Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID Reference, 4th edition, 372 pages

+ the daily Top 10


  Prostate Cancer

  Free Subscription


Articles published in J Urol

Retrieve available abstracts of 596 articles:
HTML format



Single Articles


    July 2020
  1. KINNAIRD A, Sharma V, Chuang R, Priester A, et al
    Risk of Prostate Cancer after a Negative MRI-Guided Biopsy.
    J Urol. 2020 Jul 2:101097JU0000000000001232. doi: 10.1097/JU.0000000000001232.
    PubMed     Abstract available


  2. MOSCHINI M, Rozet F
    Editorial Comment.
    J Urol. 2020;204:32.
    PubMed    


  3. KILPELAINEN T, Lahdensuo K, Rannikko A
    Editorial Comment.
    J Urol. 2020;204:32.
    PubMed    


    June 2020
  4. RESNICK MJ
    Re: Effect of a Behavioral Intervention to Increase Vegetable Consumption on Cancer Progression among Men with Early-Stage Prostate Cancer: The MEAL Randomized Clinical Trial.
    J Urol. 2020 Jun 26:101097JU0000000000001171. doi: 10.1097/JU.0000000000001171.
    PubMed    


  5. TANEJA SS
    Re: Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness.
    J Urol. 2020 Jun 26:101097JU000000000000117601.
    PubMed    


  6. TANEJA SS
    Re: Validation of a Subclassification for High-Risk Prostate Cancer in a Prospective Cohort.
    J Urol. 2020 Jun 26:101097JU0000000000001176. doi: 10.1097/JU.0000000000001176.
    PubMed    


  7. TANEJA SS
    Re: Artificial Intelligence for Diagnosis and Grading of Prostate Cancer in Biopsies: A Population-Based, Diagnostic Study.
    J Urol. 2020 Jun 26:101097JU000000000000117602.
    PubMed    


  8. REISZ PA, Laviana AA, Zhao Z, Huang LC, et al
    Assessing the Quality of Surgical Care for Clinically Localized Prostate Cancer: Results from the CEASAR Study.
    J Urol. 2020 Jun 22:101097JU0000000000001198. doi: 10.1097/JU.0000000000001198.
    PubMed     Abstract available


  9. PARK KJ, Choi SH, Lee JS, Kim JK, et al
    Inter-reader Agreement in Prostate Imaging Reporting and Data System Version 2 for Prostate Cancer: A Systematic Review and Meta-Analysis.
    J Urol. 2020 Jun 18:101097JU0000000000001200. doi: 10.1097/JU.0000000000001200.
    PubMed     Abstract available


  10. ATALA A
    Re: Long Noncoding RNA DRAIC Inhibits Prostate Cancer Progression by Interacting with IKK to Inhibit NF-kappaB Activation.
    J Urol. 2020 Jun 18:101097JU0000000000001179. doi: 10.1097/JU.0000000000001179.
    PubMed    


  11. LONERGAN PE, Washington SL 3rd, Cowan JE, Zhao S, et al
    Risk Factors for Biopsy Reclassification over Time in Men on Active Surveillance for Early Stage Prostate Cancer.
    J Urol. 2020 Jun 10:101097JU0000000000001186. doi: 10.1097/JU.0000000000001186.
    PubMed     Abstract available


  12. DENIFFEL D, Salinas E, Ientilucci M, Evans AJ, et al
    Does the Visibility of Grade Group 1 Prostate Cancer on Baseline Multiparametric Magnetic Resonance Imaging Impact Clinical Outcomes?
    J Urol. 2020 Jun 4:101097JU0000000000001157. doi: 10.1097/JU.0000000000001157.
    PubMed     Abstract available


    May 2020
  13. TANEJA SS
    Re: Influence of the Facility Caseload on the Subsequent Survival of Men with Localized Prostate Cancer Undergoing Radical Prostatectomy.
    J Urol. 2020 May 13:101097JU000000000000111502.
    PubMed    


  14. TANEJA SS
    Re: Utility of Multiparametric Magnetic Resonance Imaging in the Risk Stratification of Men with Grade Group 1 Prostate Cancer on Active Surveillance.
    J Urol. 2020 May 13:101097JU0000000000001115. doi: 10.1097/JU.0000000000001115.
    PubMed    


  15. TANEJA SS
    Re: Prostate Cancer Mortality and Metastasis under Different Biopsy Frequencies in North American Active Surveillance Cohorts.
    J Urol. 2020 May 13:101097JU000000000000111501.
    PubMed    


  16. GRIEBLING TL
    Re: Do Canadian Radiation Oncologists Consider Geriatric Assessment in the Decision-Making Process for Treatment of Patients 80 Years and Older with Non-Metastatic Prostate Cancer? National Survey.
    J Urol. 2020 May 13:101097JU000000000000110201.
    PubMed    


  17. GRIEBLING TL
    Re: Patients with Prostate Cancer and Androgen Deprivation Therapy Have Increased Risk of Fractures-A Study from the Fractures and Fall Injuries in the Elderly Cohort (FRAILCO).
    J Urol. 2020 May 13:101097JU000000000000110202.
    PubMed    


  18. GRIEBLING TL
    Re: Osteoporosis and Prostate Cancer; A 24-Month Prospective Observational Study during Androgen Deprivation Therapy.
    J Urol. 2020 May 13:101097JU000000000000110203.
    PubMed    


  19. GRIEBLING TL
    Re: Low-Value Prostate Cancer Screening among Older Men within the Veterans Health Administration.
    J Urol. 2020 May 13:101097JU0000000000001102. doi: 10.1097/JU.0000000000001102.
    PubMed    


  20. ATALA A
    Re: Galpha-13 Induces C X C Motif Chemokine Ligand 5 Expression in Prostate Cancer Cells by Transactivating NF-kappaB.
    J Urol. 2020 May 12:101097JU000000000000111702.
    PubMed    


  21. STOLZENBACH LF, Rosiello G, Deuker M, Colla-Ruvolo C, et al
    The Impact of Race and Age on Distribution of Metastases in Patients with Prostate Cancer.
    J Urol. 2020 May 12:101097JU0000000000001131. doi: 10.1097/JU.0000000000001131.
    PubMed     Abstract available


  22. CLAROS OR, Tourinho-Barbosa RR, Fregeville A, Gallardo AC, et al
    Re: Comparison of Initial Experience with Transrectal Magnetic Resonance Imaging Cognitive Guided Micro-Ultrasound Biopsies versus Established Transperineal Robotic Ultrasound Magnetic Resonance Imaging Fusion Biopsies for Prostate Cancer.
    J Urol. 2020 May 5:101097JU0000000000001123. doi: 10.1097/JU.0000000000001123.
    PubMed    


  23. MARKS LS, Natarajan S
    RE: Prostate Cancer Detection Rate of Free-hand versus 3D Template Mapping Biopsy Using an MRI/Ultrasound Fusion Device in Biopsy-Naive Men.
    J Urol. 2020 May 4:101097JU0000000000001124. doi: 10.1097/JU.0000000000001124.
    PubMed    


  24. GANDAGLIA G, Briganti A, Fossati N, Montorsi F, et al
    Re: Comparison of Initial Experience with Transrectal MRI Cognitive Guided Micro-ultrasound Biopsies versus Established Transperineal Robotic Ultrasound-Magnetic Resonance Imaging Fusion Biopsies for Prostate Cancer.
    J Urol. 2020 May 4:101097JU0000000000001122. doi: 10.1097/JU.0000000000001122.
    PubMed    


  25. SCHAEFFER EM
    Re: Multiparametric MRI Appearances of Primary Granulomatous Prostatitis.
    J Urol. 2020;203:862.
    PubMed    


  26. MARKS LS, Kinnaird A
    Editorial Comment.
    J Urol. 2020;203:924.
    PubMed    


  27. GHAI S
    Editorial Comment.
    J Urol. 2020;203:923-924.
    PubMed    


  28. SCHAEFFER EM
    Re: Sustained Influence of Infections on Prostate-Specific Antigen Concentration: An Analysis of Changes over 10 Years of Follow-up.
    J Urol. 2020;203:861-862.
    PubMed    


  29. JONES JS
    Editorial Comment.
    J Urol. 2020;203:938-939.
    PubMed    


  30. XIA L, Sperling CD, Taylor BL, Talwar R, et al
    Associations between Hospital Volume and Outcomes of Robot-Assisted Radical Prostatectomy.
    J Urol. 2020;203:926-932.
    PubMed     Abstract available


  31. POULIOT F, Rouleau M, Neveu B, Toren P, et al
    Extragonadal Steroids Contribute Significantly to Androgen Receptor Activity and Development of Castration Resistance in Recurrent Prostate Cancer after Primary Therapy.
    J Urol. 2020;203:940-948.
    PubMed     Abstract available


  32. AMIN A, Scheltema MJ, Shnier R, Blazevski A, et al
    The Magnetic Resonance Imaging in Active Surveillance (MRIAS) Trial: Use of Baseline Multiparametric Magnetic Resonance Imaging and Saturation Biopsy to Reduce the Frequency of Surveillance Prostate Biopsies.
    J Urol. 2020;203:910-917.
    PubMed     Abstract available


    April 2020
  33. ALEMOZAFFAR M, Akintayo AA, Abiodun-Ojo OA, Patil D, et al
    [(18)F]fluciclovine PET/CT for Preoperative Staging in Patients with Intermediate to High-Risk Primary Prostate Cancer.
    J Urol. 2020 Apr 29:101097JU0000000000001095. doi: 10.1097/JU.0000000000001095.
    PubMed     Abstract available


  34. DETSKY JS, Ghiam AF, Mamedov A, Commisso K, et al
    Impact of Biopsy Compliance on Outcomes for Patients on Active Surveillance for Prostate Cancer.
    J Urol. 2020 Apr 24:101097JU0000000000001091. doi: 10.1097/JU.0000000000001091.
    PubMed     Abstract available


  35. TANEJA SS
    Re: Lifetime Benefits and Harms of PSA-Based Risk Screening for Prostate Cancer.
    J Urol. 2020 Apr 15:101097JU000000000000105602.
    PubMed    


  36. TANEJA SS
    Re: Effect of a Behavioral Intervention to Increase Vegetable Consumption on Cancer Progression among Men with Early-Stage Prostate Cancer: The MEAL Randomized Clinical Trial.
    J Urol. 2020 Apr 15:101097JU0000000000001056. doi: 10.1097/JU.0000000000001056.
    PubMed    


  37. TANEJA SS
    Re: Radical Prostatectomy or Observation for Clinically Localized Prostate Cancer: Extended Follow-up of the Prostate Cancer Intervention Versus Observation Trial (PIVOT).
    J Urol. 2020 Apr 15:101097JU000000000000105601.
    PubMed    


  38. MONTORSI F, Fossati N, Gandaglia G, Briganti A, et al
    (68)Ga-PSMA-PET/CT Scan as Primary Staging for Prostate Cancer and Its Related Clinical Implications.
    J Urol. 2020 Apr 13:101097JU0000000000001081. doi: 10.1097/JU.0000000000001081.
    PubMed    


  39. ATALA A
    Re: miR-191 Promotes Radiation Resistance of Prostate Cancer through Interaction with RXRA.
    J Urol. 2020 Apr 9:101097JU000000000000105801.
    PubMed    


  40. RANASINGHE W, Reichard CA, Nyame YA, Sundi D, et al
    Downgrading from Biopsy Grade Group 4 Prostate Cancer in Patients Undergoing Radical Prostatectomy for High or Very High Risk Prostate Cancer.
    J Urol. 2020 Apr 7:101097JU0000000000001074. doi: 10.1097/JU.0000000000001074.
    PubMed     Abstract available


  41. WOO J, Santasusagna S, Banks J, Pastor-Lopez S, et al
    Urine Extracellular Vesicle GATA2 mRNA Discriminates Biopsy Result in Men with Suspicion of Prostate Cancer.
    J Urol. 2020 Apr 6:101097JU0000000000001066. doi: 10.1097/JU.0000000000001066.
    PubMed     Abstract available


  42. MARKOWSKI MC, Sedhom R, Fu W, Gray JCR, et al
    PSA and PSA Doubling Time Predict Findings on (18)F-DCFPyL PET/CT in Patients with Biochemically-Recurrent Prostate Cancer.
    J Urol. 2020 Apr 6:101097JU0000000000001064. doi: 10.1097/JU.0000000000001064.
    PubMed     Abstract available


  43. BONDE MIRANDA T, Garmo H, Stattin P, Robinson D, et al
    5alpha-Reductase Inhibitors and Risk of Prostate Cancer Death.
    J Urol. 2020 Apr 3:101097JU0000000000001038. doi: 10.1097/JU.0000000000001038.
    PubMed     Abstract available


  44. TOSOIAN JJ
    Editorial Comment.
    J Urol. 2020;203:732.
    PubMed    


  45. KLAASSEN Z, Wallis CJD
    Editorial Comment.
    J Urol. 2020;203:758-759.
    PubMed    


  46. STEYERBERG EW
    Editorial Comment.
    J Urol. 2020;203:726.
    PubMed    


  47. MEHRALIVAND S
    Editorial Comment.
    J Urol. 2020;203:725-726.
    PubMed    


  48. LEAPMAN M
    Editorial Comment.
    J Urol. 2020;203:705.
    PubMed    


  49. NELSON M, Dornbier R, Kirshenbaum E, Eguia E, et al
    Use of Surgery for Post-Prostatectomy Incontinence.
    J Urol. 2020;203:786-791.
    PubMed     Abstract available


    March 2020
  50. WANG WW, Sorokin I, Aleksic I, Mian B, et al
    Expression of Small Non-coding RNAs in Urinary Exosomes Classifies Prostate Cancer into Indolent and Aggressive Disease.
    J Urol. 2020 Mar 19:101097JU0000000000001020. doi: 10.1097/JU.0000000000001020.
    PubMed     Abstract available


  51. HALSTUCH D, Ber Y, Kedar D, Golan S, et al
    Short-Term Outcomes of Active Surveillance for Low-Risk Prostate Cancer Among Men with Germline DNA Repair Gene Mutations.
    J Urol. 2020 Mar 19:101097JU0000000000001027. doi: 10.1097/JU.0000000000001027.
    PubMed     Abstract available


  52. TANEJA SS
    Re: Statin Use is Associated with Lower Risk of PTEN-Null and Lethal Prostate Cancer.
    J Urol. 2020 Mar 18:101097JU0000000000001000. doi: 10.1097/JU.0000000000001000.
    PubMed    


  53. NAHAR B, Bhat A, Reis IM, Soodana-Prakash N, et al
    Prospective Evaluation of Focal High-Intensity Focused Ultrasound (HIFU) for Patients with Localized Prostate Cancer.
    J Urol. 2020 Mar 13:101097JU0000000000001015. doi: 10.1097/JU.0000000000001015.
    PubMed     Abstract available


  54. MARRA G, Moschini M, Cathelineau X, Sanchez-Salas R, et al
    Re: Hemigland Cryoablation of Localized Low-, Intermediate- and High-Risk Prostate Cancer: Oncologic and Functional Outcomes at 5 Years.
    J Urol. 2020 Mar 6:101097JU0000000000001008. doi: 10.1097/JU.0000000000001008.
    PubMed    


  55. ABREU AL, Oishi M, Tafuri A, Shakir A, et al
    RE: Hemigland Cryoablation of Localized Low, Intermediate and High Risk Prostate Cancer: Oncologic and Functional Outcomes at 5 Years.
    J Urol. 2020 Mar 6:101097JU0000000000001009. doi: 10.1097/JU.0000000000001009.
    PubMed    


  56. VERTOSICK EA, Haggstrom C, Sjoberg DD, Hallmans G, et al
    Prespecified Four Kallikrein Marker Model (4Kscore) at Age 50 or 60 for Early Detection of Lethal Prostate Cancer in a Large Population-Based Cohort of Asymptomatic Men Followed for 20 Years.
    J Urol. 2020 Mar 3:101097JU0000000000001007. doi: 10.1097/JU.0000000000001007.
    PubMed     Abstract available


  57. IRAVANI A
    Editorial Comment.
    J Urol. 2020;203:544-545.
    PubMed    


  58. SIEGEL C
    Re: A Review of the Principles of Texture Analysis and its Role in Imaging of Genitourinary Neoplasms.
    J Urol. 2020;203:444.
    PubMed    


  59. BAUNACKE M, Schmidt ML, Groeben C, Borkowetz A, et al
    Decision Regret after Radical Prostatectomy does Not Depend on Surgical Approach: 6-Year Followup of a Large German Cohort Undergoing Routine Care.
    J Urol. 2020;203:554-561.
    PubMed     Abstract available


  60. GROSS MD, Marks LS, Sonn GA, Green DA, et al
    Variation in Magnetic Resonance Imaging-Ultrasound Fusion Targeted Biopsy Outcomes in Asian American Men: A Multicenter Study.
    J Urol. 2020;203:530-536.
    PubMed     Abstract available


  61. CHAPPIDI MR, Stimson CJ, Kates M, Odisho AY, et al
    A Nationally Representative Study of Nonindex Hospital Readmissions following Radical Prostatectomy: Implications for Bundled Payment Models.
    J Urol. 2020;203:546-553.
    PubMed     Abstract available


    February 2020
  62. SAAD F, Fleshner N, Pickles T, Niazi T, et al
    Testosterone Breakthrough Rates during Androgen Deprivation Therapy for Castration Sensitive Prostate Cancer.
    J Urol. 2020 Feb 25:101097JU0000000000000809. doi: 10.1097/JU.0000000000000809.
    PubMed     Abstract available


  63. OAKE JD, Shiff B, Harasemiw O, Tangri N, et al
    The Comparative Outcomes of Radical Prostatectomy versus Radiotherapy for Non-metastatic Prostate Cancer: A Longitudinal, Population-Based Analysis.
    J Urol. 2020 Feb 18:101097JU0000000000000805. doi: 10.1097/JU.0000000000000805.
    PubMed     Abstract available


  64. INABA H, Kimura T, Onuma H, Sato S, et al
    Tumor Location and Pathological Features of Latent and Incidental Prostate Cancer in Contemporary Japanese Men.
    J Urol. 2020 Feb 18:101097JU0000000000000804. doi: 10.1097/JU.0000000000000804.
    PubMed     Abstract available


  65. STUOPELYTE K, Sabaliauskaite R, Bakavicius A, Haflidadottir BS, et al
    Analysis of AR-FL and AR-V1 in Whole Blood of Patients with Castration Resistant Prostate Cancer as a Tool for Predicting Response to Abiraterone Acetate.
    J Urol. 2020 Feb 18:101097JU0000000000000803. doi: 10.1097/JU.0000000000000803.
    PubMed     Abstract available


  66. FOSSATI N, Scarcella S, Gandaglia G, Suardi N, et al
    Underestimation of PET/CT Scan in Assessing Tumour Burden of Men With Nodal Recurrence From Prostate Cancer: Head-to-Head Comparison OF (68)Ga-PSMA and (11)C-Choline in a Large, Multi-Institutional Series of Extended Salvage Lymph Node Dissections.
    J Urol. 2020 Feb 18:101097JU0000000000000800. doi: 10.1097/JU.0000000000000800.
    PubMed     Abstract available


  67. KAPLAN SA
    Re: Impact of 5alpha-Reductase Inhibitor and alpha-Blocker Therapy for Benign Prostatic Hyperplasia on Prostate Cancer Incidence and Mortality.
    J Urol. 2020 Feb 13:101097JU000000000000076302.
    PubMed    


  68. TANEJA SS
    Re: Ten-Year Mortality, Disease Progression, and Treatment-Related Side Effects in Men with Localised Prostate Cancer from the ProtecT Randomised Controlled Trial According to Treatment Received.
    J Urol. 2020 Feb 13:101097JU000000000000077902.
    PubMed    


  69. TANEJA SS
    Re: Long Term Follow-up and Outcomes of Re-Treatment in an Expanded 50 Patient Single-Center Phase II Prospective Trial of Lutetium-177 ((177)Lu) PSMA-617 Theranostics in Metastatic Castrate-Resistant Prostate Cancer.
    J Urol. 2020 Feb 13:101097JU000000000000077901.
    PubMed    


  70. TANEJA SS
    Re: Comparison of Targeted vs Systematic Prostate Biopsy in Men Who Are Biopsy Naive: The Prospective Assessment of Image Registration in the Diagnosis of Prostate Cancer (PAIREDCAP) Study.
    J Urol. 2020 Feb 13:101097JU0000000000000779. doi: 10.1097/JU.0000000000000779.
    PubMed    


  71. ATALA A
    Re: High-Fat Diet Fuels Prostate Cancer Progression by Rewiring the Metabolome and Amplifying the MYC Program.
    J Urol. 2020 Feb 12:101097JU000000000000078102.
    PubMed    


  72. SIEGEL C
    Re: Diagnostic Value of CT in Detecting Peripheral Zone Prostate Cancer.
    J Urol. 2020 Feb 10:101097JU0000000000000766. doi: 10.1097/JU.0000000000000766.
    PubMed    


  73. SATKUNASIVAM R, Miles BJ
    Editorial Comment.
    J Urol. 2020;203:329.
    PubMed    


  74. PERLIS N
    Editorial Comment.
    J Urol. 2020;203:329.
    PubMed    


  75. TANEJA SS
    Re: Reasons for Discontinuing Active Surveillance: Assessment of 21 Centres in 12 Countries in the Movember GAP3 Consortium.
    J Urol. 2020;203:252-253.
    PubMed    


  76. CADEDDU JA
    Re: Robot-Assisted Radical Prostatectomy after Focal Therapy: Oncological, Functional Outcomes and Predictors of Recurrence.
    J Urol. 2020;203:233.
    PubMed    


  77. HANEY NM, Faisal FA, Lu J, Guedes LB, et al
    PTEN Loss with ERG Negative Status is Associated with Lethal Disease after Radical Prostatectomy.
    J Urol. 2020;203:344-350.
    PubMed     Abstract available


  78. ABEDALI ZA, Calaway AC, Large T, Lingeman JE, et al
    The Role of Prostate Specific Antigen Monitoring after Holmium Laser Enucleation of the Prostate.
    J Urol. 2020;203:304-310.
    PubMed     Abstract available


  79. ERICSON KJ, Wu SS, Lundy SD, Thomas LJ, et al
    Diagnostic Accuracy of Prostate Biopsy for Detecting Cribriform Gleason Pattern 4 Carcinoma and Intraductal Carcinoma in Paired Radical Prostatectomy Specimens: Implications for Active Surveillance.
    J Urol. 2020;203:311-319.
    PubMed     Abstract available


  80. ZHAO H, Howard LE, De Hoedt A, Terris MK, et al
    Racial Discrepancies in Overall Survival among Men Treated with (223)Radium.
    J Urol. 2020;203:331-337.
    PubMed     Abstract available


  81. DENIFFEL D, Zhang Y, Salinas E, Satkunasivam R, et al
    Reducing Unnecessary Prostate Multiparametric Magnetic Resonance Imaging by Using Clinical Parameters to Predict Negative and Indeterminate Findings.
    J Urol. 2020;203:292-298.
    PubMed     Abstract available


  82. PREISSER F, van den Bergh RCN, Gandaglia G, Ost P, et al
    Effect of Extended Pelvic Lymph Node Dissection on Oncologic Outcomes in Patients with D'Amico Intermediate and High Risk Prostate Cancer Treated with Radical Prostatectomy: A Multi-Institutional Study.
    J Urol. 2020;203:338-343.
    PubMed     Abstract available


  83. ALDER R, Zetner D, Rosenberg J
    Incidence of Inguinal Hernia after Radical Prostatectomy: A Systematic Review and Meta-Analysis.
    J Urol. 2020;203:265-274.
    PubMed     Abstract available


    January 2020
  84. JANSSON F, Folkvaljon F, Stattin P, Bratt O, et al
    Risk of Postoperative Upstaging or Upgrading Among Men with Low-Risk Familial Prostate Cancer.
    J Urol. 2020 Jan 31:101097JU0000000000000793. doi: 10.1097/JU.0000000000000793.
    PubMed     Abstract available


  85. LOUGHLIN KR
    Re: Undertreatment of Prostate Cancer in Rural Locations.
    J Urol. 2020 Jan 27:101097JU0000000000000759. doi: 10.1097/JU.0000000000000759.
    PubMed    


  86. WATSON V, McCartan N, Krucien N, Abu V, et al
    Evaluating the Trade-offs Men with Localised Prostate Cancer Make Between the Risks and Benefits of Treatments: The COMPARE Study.
    J Urol. 2020 Jan 22:101097JU0000000000000754. doi: 10.1097/JU.0000000000000754.
    PubMed     Abstract available


  87. ATALA A
    Re: Selective Targeting of PARP-2 Inhibits Androgen Receptor Signaling and Prostate Cancer Growth through Disruption of FOXA1 Function.
    J Urol. 2020 Jan 13:101097JU0000000000000732. doi: 10.1097/JU.0000000000000732.
    PubMed    


  88. ATALA A
    Re: The Polycomb Repressor Complex 1 Drives Double-Negative Prostate Cancer Metastasis by Coordinating Stemness and Immune Suppression.
    J Urol. 2020 Jan 13:101097JU000000000000073201.
    PubMed    


  89. TANEJA SS
    Re: Risk of Prostate Cancer for Men Fathering through Assisted Reproduction: Nationwide Population Based Register Study.
    J Urol. 2020 Jan 13:101097JU000000000000073002.
    PubMed    


  90. TANEJA SS
    Re: Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer.
    J Urol. 2020 Jan 13:101097JU000000000000073001.
    PubMed    


  91. ELLIOTT S
    Re: Salvage Brachytherapy for Locally-Recurrent Prostate Cancer after Radiation Therapy: A Comparison of Efficacy and Toxicity Outcomes with High-Dose Rate and Low-Dose Rate Brachytherapy.
    J Urol. 2020 Jan 13:101097JU000000000000074501.
    PubMed    


  92. HUBER PM, Afzal N, Arya M, Boxler S, et al
    PSA Criteria to Diagnose Failure of Cancer Control following Focal Therapy for Non-metastatic Prostate Cancer Using High Intensity Focused Ultrasound.
    J Urol. 2020 Jan 13:101097JU0000000000000747. doi: 10.1097/JU.0000000000000747.
    PubMed     Abstract available


  93. CARLSSON S, Benfante N, Alvim R, Sjoberg DD, et al
    Risk of Metastasis in Men with Grade Group 2 Prostate Cancer Managed with Active Surveillance at a Tertiary Cancer Center.
    J Urol. 2020 Jan 7:101097JU0000000000000742. doi: 10.1097/JU.0000000000000742.
    PubMed     Abstract available


  94. LEONG DP, Fradet V, Shayegan B, Duceppe E, et al
    Cardiovascular Risk in Men with Prostate Cancer: Insights from the RADICAL PC Study.
    J Urol. 2020 Jan 3:101097JU0000000000000714. doi: 10.1097/JU.0000000000000714.
    PubMed     Abstract available


  95. TANEJA SS
    Re: Gold Nanoshell-Localized Photothermal Ablation of Prostate Tumors in a Clinical Pilot Device Study.
    J Urol. 2020;203:31.
    PubMed    


  96. EMMETT L, Hofman MS
    Editorial Comment.
    J Urol. 2020;203:99.
    PubMed    


  97. HAMILTON RJ
    Editorial Comment.
    J Urol. 2020;203:126-127.
    PubMed    


  98. LOEB S, Cazzaniga W, Robinson D, Garmo H, et al
    Opioid Use after Radical Prostatectomy: Nationwide, Population Based Study in Sweden.
    J Urol. 2020;203:145-150.
    PubMed     Abstract available


  99. FILSON CP
    Editorial Comment.
    J Urol. 2020;203:135.
    PubMed    


  100. ZAMBRANO IA, Tan HJ
    Editorial Comment.
    J Urol. 2020;203:135-136.
    PubMed    


  101. TODENHOFER T
    Editorial Comment.
    J Urol. 2020;203:81.
    PubMed    


  102. XU J, Helfand BT
    Editorial Comment.
    J Urol. 2020;203:80-81.
    PubMed    


  103. LEE J, Kim HY, Goh HJ, Heo JE, et al
    Retzius Sparing Robot-Assisted Radical Prostatectomy Conveys Early Regain of Continence over Conventional Robot-Assisted Radical Prostatectomy: A Propensity Score Matched Analysis of 1,863 Patients.
    J Urol. 2020;203:137-144.
    PubMed     Abstract available


  104. LOVEGROVE CE, Miah S, El-Shater Bosaily A, Bott S, et al
    Comparison of Transrectal Ultrasound Biopsy to Transperineal Template Mapping Biopsies Stratified by Multiparametric Magnetic Resonance Imaging Score in the PROMIS Trial.
    J Urol. 2020;203:100-107.
    PubMed     Abstract available


    December 2019
  105. CARLSSON S, Benfante N, Alvim R, Sjoberg DD, et al
    Long-Term Outcomes of Active Surveillance for Prostate Cancer - The Memorial Sloan Kettering Cancer Center Experience.
    J Urol. 2019 Dec 23:101097JU0000000000000713. doi: 10.1097/JU.0000000000000713.
    PubMed     Abstract available


  106. PAK S, Suh YS, Lee DE, Kim SH, et al
    Association Between Postoperative Detection of Circulating Tumor Cells and Recurrence in Patients with Prostate Cancer.
    J Urol. 2019 Dec 17:101097JU0000000000000704. doi: 10.1097/JU.0000000000000704.
    PubMed     Abstract available


  107. SHAH N, Ioffe V
    Re: Personalized Risks of Over Diagnosis for Screen Detected Prostate Cancer Incorporating Patient Comorbidities: Estimation and Communication.
    J Urol. 2019 Dec 17:101097JU0000000000000702. doi: 10.1097/JU.0000000000000702.
    PubMed    


  108. GULATI R, Etzioni R
    Re: Personalized Risks of Over Diagnosis for Screen Detected Prostate Cancer Incorporating Patient Comorbidities: Estimation and Communication.
    J Urol. 2019 Dec 17:101097JU0000000000000703. doi: 10.1097/JU.0000000000000703.
    PubMed    


  109. TANEJA SS
    Re: Metastasis-Directed Therapy in Treating Nodal Oligorecurrent Prostate Cancer: A Multi-Institutional Analysis Comparing the Outcome and Toxicity of Stereotactic Body Radiotherapy and Elective Nodal Radiotherapy.
    J Urol. 2019 Dec 12:101097JU000000000000067701.
    PubMed    


  110. TANEJA SS
    Re: Prostate Cancer Risks for Male BRCA1 and BRCA2 Mutation Carriers: A Prospective Cohort Study.
    J Urol. 2019 Dec 12:101097JU000000000000067702.
    PubMed    


  111. TANEJA SS
    Re: Transcriptomic Heterogeneity of Androgen Receptor Activity Defines a de Novo Low AR-Active Subclass in Treatment Naive Primary Prostate Cancer.
    J Urol. 2019 Dec 12:101097JU0000000000000677. doi: 10.1097/JU.0000000000000677.
    PubMed    


  112. GRIEBLING TL
    Re: Gay Men's Experiences of Sexual Changes after Prostate Cancer Treatment-A Qualitative Study in Sweden.
    J Urol. 2019 Dec 12:101097JU000000000000066404.
    PubMed    


  113. CLAROS OR, Tourinho-Barbosa RR, Fregeville A, Gallardo AC, et al
    Comparison of Initial Experience with Transrectal MRI Cognitive Guided Micro-ultrasound Biopsies versus Established Transperineal Robotic Ultrasound-Magnetic Resonance Imaging Fusion Biopsies for Prostate Cancer.
    J Urol. 2019 Dec 10:101097JU0000000000000692. doi: 10.1097/JU.0000000000000692.
    PubMed     Abstract available


  114. ATALA A
    Re: Betaglycan Drives the Mesenchymal Stromal Cell Osteogenic Program and Prostate Cancer-Induced Osteogenesis.
    J Urol. 2019 Dec 3:101097JU0000000000000679. doi: 10.1097/JU.0000000000000679.
    PubMed    


  115. ATALA A
    Re: The Androgen Receptor Regulates a Druggable Translational Regulon in Advanced Prostate Cancer.
    J Urol. 2019 Dec 3:101097JU000000000000067901.
    PubMed    


  116. FAROLFI A, Gafita A, Calais J, Eiber M, et al
    Reply by Authors.
    J Urol. 2019;202:1181.
    PubMed    


  117. OISHI M, Gill IS, Tafuri A, Shakir A, et al
    Reply by Authors.
    J Urol. 2019;202:1198.
    PubMed    


  118. KAPOOR J, Koschel S, Murphy DG
    Editorial Comment.
    J Urol. 2019;202:1180-1181.
    PubMed    


  119. CHIN JL
    Editorial Comment.
    J Urol. 2019;202:1197-1198.
    PubMed    


  120. SCATTONI V
    Editorial Comment.
    J Urol. 2019;202:1172.
    PubMed    


  121. MANNAERTS CK, Wildeboer RR, Remmers S, van Kollenburg RAA, et al
    Reply by Authors.
    J Urol. 2019;202:1172-1173.
    PubMed    


  122. ALCARAZ KI
    Editorial Comment.
    J Urol. 2019;202:1215-1216.
    PubMed    


  123. KILPELAINEN TP, Jarvinen P, Tikkinen KAO
    Randomized Trials Show a Consistent Benefit of Radical Prostatectomy on Mortality Outcomes.
    J Urol. 2019;202:1106-1108.
    PubMed    


  124. PLOUSSARD G, Beauval JB, Lesourd M, Almeras C, et al
    Added Value of Concomitant Systematic and Fusion Targeted Biopsies for Grade Group Prediction Based on Radical Prostatectomy Final Pathology on Positive Magnetic Resonance Imaging.
    J Urol. 2019;202:1182-1187.
    PubMed     Abstract available


  125. LO G, Burton KR, Haider MA, Fleshner N, et al
    Negative Predictive Value of Prostate Multiparametric Magnetic Resonance Imaging among Men with Negative Prostate Biopsy and Elevated Prostate Specific Antigen: A Clinical Outcome Retrospective Cohort Study.
    J Urol. 2019;202:1159-1165.
    PubMed     Abstract available


  126. AL HUSSEIN AL AWAMLH B, Shoag JE, Ravikumar V, Posada L, et al
    Association of Smoking and Death from Genitourinary Malignancies: Analysis of the National Longitudinal Mortality Study.
    J Urol. 2019;202:1248-1254.
    PubMed     Abstract available


    November 2019
  127. WEINER AB, Cohen JE, DeLancey JO, Schaeffer EM, et al
    Surgical Versus Medical Castration for Metastatic Prostate Cancer: Use and Overall Survival in a National Cohort.
    J Urol. 2019 Nov 20:101097JU0000000000000684. doi: 10.1097/JU.0000000000000684.
    PubMed     Abstract available


  128. DRAULANS C, Everaerts W, Isebaert S, Van Bruwaene S, et al
    Development and External Validation of a mpMRI- and ISUP-Based Add-on Prediction Tool to Identity Prostate Cancer Candidates for Pelvic Lymph Node Dissection.
    J Urol. 2019 Nov 13:101097JU0000000000000652. doi: 10.1097/JU.0000000000000652.
    PubMed     Abstract available


  129. GRIEBLING TL
    Re: Effect of Androgen Deprivation Therapy on Other-Cause of Mortality in Elderly Patients with Clinically Localized Prostate Cancer Treated with Modern Radiotherapy: Is There a Negative Impact?
    J Urol. 2019 Nov 11:10109701JU000061471212731.
    PubMed    


  130. TANEJA SS
    Re: Oncological and Quality-of-Life Outcomes following Focal Irreversible Electroporation as Primary Treatment for Localised Prostate Cancer: A Biopsy-Monitored Prospective Cohort.
    J Urol. 2019 Nov 11:10109701JU000061489640156.
    PubMed    


  131. TANEJA SS
    Re: Diagnostic Accuracy of Multiparametric MRI versus 68Ga-PSMA-11 PET/MRI for Extracapsular Extension and Seminal Vesicle Invasion in Patients with Prostate Cancer.
    J Urol. 2019 Nov 11:10109701JU000061489258082.
    PubMed    


  132. GRIEBLING TL
    Re: How to Choose Proper Local Treatment in Men Aged >/=75 Years with cT2 Localized Prostate Cancer?
    J Urol. 2019 Nov 11:10109701JU0000614720060019.
    PubMed    


  133. GRIEBLING TL
    Re: Intensity-Modulated Radiation Therapy for Elderly Patients (Aged >/=75 Years) with Localized Prostate Cancer: Comparison with Younger Patients (Aged <75 Years).
    J Urol. 2019 Nov 11:101097JU0000000000000639. doi: 10.1097/JU.0000000000000639.
    PubMed    


  134. GRIEBLING TL
    Re: Safety and Outcomes of New Generation Hormone-Therapy in Elderly Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer Patients in the Real World.
    J Urol. 2019 Nov 11:10109701JU00006147169837619.
    PubMed    


  135. GRIEBLING TL
    Re: Risk of Cardiovascular Events in Men Treated for Prostate Cancer Compared with Prostate Cancer-Free Men.
    J Urol. 2019 Nov 9:10109701JU00006147248807477.
    PubMed    


  136. MARCHIONI M, Di Nicola M, Primiceri G, Novara G, et al
    New Anti-Androgen Compounds Compared to Docetaxel in Metastatic Hormone Sensitive Prostate Cancer: Results from a Network Meta-Analysis.
    J Urol. 2019 Nov 5:101097JU0000000000000636. doi: 10.1097/JU.0000000000000636.
    PubMed     Abstract available


  137. ATALA A
    Re: Dysregulation of p53-RBM25-Mediated circAMOTL1L Biogenesis Contributes to Prostate Cancer Progression through the circAMOTL1L-miR-193a-5p-Pcdha Pathway.
    J Urol. 2019 Nov 4:10109701JU0000613432221690.
    PubMed    


  138. PENSON DF
    Editorial Comment.
    J Urol. 2019;202:972.
    PubMed    


  139. WANG S, Siddiqui MM
    Editorial Comment.
    J Urol. 2019;202:951.
    PubMed    


  140. EGGENER S
    Editorial Comment.
    J Urol. 2019;202:942-943.
    PubMed    


  141. GHAI S
    Editorial Comment.
    J Urol. 2019;202:957.
    PubMed    


  142. JONES JS
    Editorial Comment.
    J Urol. 2019;202:957-958.
    PubMed    


  143. GROSS MD, Sedrakyan A, Bianco FJ, Carroll PR, et al
    Reply by Authors.
    J Urol. 2019;202:958.
    PubMed    


  144. GULATI R, Psutka SP, Etzioni R
    Reply by Authors.
    J Urol. 2019;202:943.
    PubMed    


    October 2019
  145. SABA K, Wettstein MS, Lieger L, Hotker AM, et al
    External Validation and Comparison of Prostate Cancer Risk Calculators Incorporating Multiparametric Magnetic Resonance Imaging for Prediction of Clinically Significant Prostate Cancer.
    J Urol. 2019 Oct 25:101097JU0000000000000622. doi: 10.1097/JU.0000000000000622.
    PubMed     Abstract available


  146. SCHENK JM, Newcomb LF, Zheng Y, Faino AV, et al
    African American Race is Not Associated with Risk of Reclassification during Active Surveillance: Results from the Canary Prostate Cancer Active Surveillance Study (PASS).
    J Urol. 2019 Oct 25:101097JU0000000000000621. doi: 10.1097/JU.0000000000000621.
    PubMed     Abstract available


  147. BJURLIN MA, Carroll PR, Eggener S, Fulgham PF, et al
    Update of the AUA Policy Statement on the Use of Multiparametric Magnetic Resonance Imaging in the Diagnosis, Staging and Management of Prostate Cancer.
    J Urol. 2019 Oct 23:101097JU0000000000000617. doi: 10.1097/JU.0000000000000617.
    PubMed     Abstract available


  148. RESNICK MJ
    Re: Urologist Practice Structure and Spending for Prostate Cancer Care.
    J Urol. 2019 Oct 21:10109701JU0000611480517223.
    PubMed    


  149. TANEJA SS
    Re: Ultra-Hypofractionated versus Conventionally Fractionated Radiotherapy for Prostate Cancer: 5-Year Outcomes of the HYPO-RT-PC Randomised, Non-Inferiority, Phase 3 Trial.
    J Urol. 2019 Oct 21:10109701JU000061150033954.
    PubMed    


  150. TANEJA SS
    Re: Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer.
    J Urol. 2019 Oct 21:10109701JU000061150441578.
    PubMed    


  151. GRIEBLING TL
    Re: Sarcopenia is a Poor Prognostic Factor of Castration-Resistant Prostate Cancer Treated with Docetaxel Therapy.
    J Urol. 2019 Oct 17:10109701JU0000604840216814.
    PubMed    


  152. ATALA A
    Re: Distinct Structural Classes of Activating FOXA1 Alterations in Advanced Prostate Cancer.
    J Urol. 2019 Oct 16:10109701JU00006047967711890.
    PubMed    


  153. GOLDBERG H, Ahmad AE, Chandrasekar T, Klotz L, et al
    Comparison of MRI- and TRUS-Informed Prostate Biopsy for Prostate Cancer Diagnosis in Biopsy-Naive Men: A Systematic Review and Meta-Analysis.
    J Urol. 2019 Oct 14:101097JU0000000000000595. doi: 10.1097/JU.0000000000000595.
    PubMed     Abstract available


  154. ZHOU SR, Chang E, Patankar A, Huang J, et al
    Prostate Cancer Detection Rate of Free-hand versus 3D Template Mapping Biopsy Using an MRI/Ultrasound Fusion Device in Biopsy-Naive Men.
    J Urol. 2019 Oct 9:101097JU0000000000000587. doi: 10.1097/JU.0000000000000587.
    PubMed     Abstract available


  155. DASKIVICH TJ, Thomas IC, Leppert JT
    Reply to Letter to the Editor Re: External Validation of the Prostate Cancer-specific Comorbidity Index (PCCI), a Claims-Based Tool for Prediction of Life Expectancy in Men with Prostate Cancer.
    J Urol. 2019 Oct 9:101097JU0000000000000586. doi: 10.1097/JU.0000000000000586.
    PubMed    


  156. FROEHNER M, Koch R, Thomas C
    Life Expectancy in Men with Prostate Cancer.
    J Urol. 2019 Oct 9:101097JU0000000000000585. doi: 10.1097/JU.0000000000000585.
    PubMed    


  157. CRAWFORD ED, Twardowski PW, Concepcion RS, Hafron JM, et al
    The Impact of Late LHRH Agonist Dosing on Testosterone Suppression in Prostate Cancer Patients: An Analysis of US Clinical Data.
    J Urol. 2019 Oct 3:101097JU0000000000000577. doi: 10.1097/JU.0000000000000577.
    PubMed     Abstract available


  158. KAPLAN SA
    Re: Serum Cholesterol and Risk of Lower Urinary Tract Symptoms Progression: Results from the Reduction by Dutasteride of Prostate Cancer Events Study.
    J Urol. 2019;202:635.
    PubMed    


  159. MURRAY NP
    Editorial Comment.
    J Urol. 2019;202:740-741.
    PubMed    


  160. EGGER S
    Editorial Comment.
    J Urol. 2019;202:695.
    PubMed    


  161. TANEJA SS
    Re: Evaluation of Intense Androgen Deprivation before Prostatectomy: A Randomized Phase II Trial of Enzalutamide and Leuprolide with or without Abiraterone.
    J Urol. 2019;202:662.
    PubMed    


  162. PEDERZOLI F, Bandini M
    Editorial Comment.
    J Urol. 2019;202:716.
    PubMed    


  163. MONTIRONI R, Scarpelli M
    Editorial Comment.
    J Urol. 2019;202:715-716.
    PubMed    


  164. KLEIN EA
    Editorial Comment.
    J Urol. 2019;202:701.
    PubMed    


  165. KORNBERG Z, Cooperberg MR, Cowan JE, Chan JM, et al
    A 17-Gene Genomic Prostate Score as a Predictor of Adverse Pathology in Men on Active Surveillance.
    J Urol. 2019;202:702-709.
    PubMed     Abstract available


    September 2019
  166. TANEJA SS
    Re: Genomic Correlates of Clinical Outcome in Advanced Prostate Cancer.
    J Urol. 2019 Sep 18:10109701JU0000585744961900.
    PubMed    


  167. TANEJA SS
    Re: Alcohol Intake and Risk of Lethal Prostate Cancer in the Health Professionals Follow-Up Study.
    J Urol. 2019 Sep 18:10109701JU000058574803815.
    PubMed    


  168. RESNICK MJ
    Re: Self-Management in Long-Term Prostate Cancer Survivors: A Randomized, Controlled Trial.
    J Urol. 2019 Sep 13:101097JU0000000000000550. doi: 10.1097/JU.0000000000000550.
    PubMed    


  169. ATALA A
    Re: Communication of Prostate Cancer Cells with Bone Cells via Extracellular Vesicle RNA; a Potential Mechanism of Metastasis.
    J Urol. 2019 Sep 12:10109701JU0000585156807772.
    PubMed    


  170. WEINSTOCK C, Suzman D, Kluetz P, Baxley J, et al
    Development of Treatments for Localized Prostate Cancer in Patients Eligible for Active Surveillance: FDA Oncology Center of Excellence Public Workshop.
    J Urol. 2019 Sep 10:101097JU0000000000000532. doi: 10.1097/JU.0000000000000532.
    PubMed     Abstract available


  171. VAN KALMTHOUT LWM, van Melick HHE, Lavalaye J, Meijer RP, et al
    Prospective Validation of Gallium-68 PSMA-PET/CT in Primary Staging of Prostate Cancer Patients.
    J Urol. 2019 Sep 5:101097JU0000000000000531. doi: 10.1097/JU.0000000000000531.
    PubMed     Abstract available


  172. LEYH-BANNURAH SR, Kachanov M, Beyersdorff D, Tian Z, et al
    Minimum Number of MRI Ultrasound Fusion Targeted Biopsy Cores Needed for Prostate Cancer Detection: Multivariable Retrospective Lesion-Based Analyses of Patients Treated with Radical Prostatectomy.
    J Urol. 2019 Sep 4:101097JU0000000000000527. doi: 10.1097/JU.0000000000000527.
    PubMed     Abstract available


  173. PAK S, Park SY, Shin TJ, You D, et al
    Reply by Authors.
    J Urol. 2019;202:531-532.
    PubMed    


  174. O'NEILL M, Alibhai SMH
    Editorial Comment.
    J Urol. 2019;202:530-531.
    PubMed    


  175. KARAKIEWICZ PI
    Editorial Comment.
    J Urol. 2019;202:531.
    PubMed    


  176. GORE JL
    Editorial Comment.
    J Urol. 2019;202:524.
    PubMed    


  177. STOYANOVA R
    Editorial Comment.
    J Urol. 2019;202:505.
    PubMed    


  178. NAYAN M, Fleshner N, Bozzo A
    Editorial Comment.
    J Urol. 2019;202:504-505.
    PubMed    


  179. PISANSKY TM, Thompson IM, Valicenti RK, D'Amico AV, et al
    Adjuvant and Salvage Radiotherapy after Prostatectomy: ASTRO/AUA Guideline Amendment 2018-2019.
    J Urol. 2019;202:533-538.
    PubMed     Abstract available


  180. VECCIA A, Antonelli A, Francavilla S, Porpiglia F, et al
    Minimally Invasive Radical Prostatectomy after Previous Bladder Outlet Surgery: A Systematic Review and Pooled Analysis of Comparative Studies.
    J Urol. 2019;202:511-517.
    PubMed     Abstract available


  181. BALAKRISHNAN AS, Cowan JE, Cooperberg MR, Shinohara K, et al
    Evaluating the Safety of Active Surveillance: Outcomes of Deferred Radical Prostatectomy after an Initial Period of Surveillance.
    J Urol. 2019;202:506-510.
    PubMed     Abstract available


    August 2019
  182. TOURINHO-BARBOSA RR, Sanchez-Salas R, Claros OR, Collura-Merlier S, et al
    Focal Therapy for Localized Prostate Cancer with Either HIFU or Cryoablation: A Single Institution Experience.
    J Urol. 2019 Aug 22:101097JU0000000000000506. doi: 10.1097/JU.0000000000000506.
    PubMed     Abstract available


  183. DAMBAL S, Howard LE, Allott EH, Aronson WJ, et al
    Serum Lipids Prior to Starting Androgen Deprivation Therapy and Risk of Castration-Resistant Prostate Cancer and Metastasis: Results from the SEARCH Database.
    J Urol. 2019 Aug 20:101097JU0000000000000494. doi: 10.1097/JU.0000000000000494.
    PubMed     Abstract available


  184. ITO K, Yokomizo A, Tokunaga S, Arai G, et al
    Diagnostic Impacts of Clinical Laboratory-Based [-2] proPSA Indices on Any Grade, Gleason Grade Group >/=2 or >/=3 of Prostate Cancer in the PSA Below 10 ng/mL.
    J Urol. 2019 Aug 20:101097JU0000000000000495. doi: 10.1097/JU.0000000000000495.
    PubMed     Abstract available


  185. BAHLER CD, Green M, Hutchins GD, Cheng L, et al
    PSMA-Targeted Positron Emission Tomography (PET) in Evaluation of Patients with Primary Prostate Cancer: Comparison of Pre-operative [(68)Ga]Ga-PSMA-11 PET/CT, Immediate Post-operative Specimen [(68)Ga]Ga-PSMA-11 Imaging, and Whole Mount Pathology.
    J Urol. 2019 Aug 20:101097JU0000000000000501. doi: 10.1097/JU.0000000000000501.
    PubMed     Abstract available


  186. MAGANTY A, Sabik LM, Sun Z, Eom KY, et al
    Undertreatment of Prostate Cancer in Rural Residents.
    J Urol. 2019 Aug 20:101097JU0000000000000500. doi: 10.1097/JU.0000000000000500.
    PubMed     Abstract available


  187. TANEJA SS
    Re: Association of Treatment with 5alpha-Reductase Inhibitors with Time to Diagnosis and Mortality in Prostate Cancer.
    J Urol. 2019 Aug 12:10109701JU000058011614376.
    PubMed    


  188. KAPLAN SA
    Re: Association of Treatment with 5alpha-Reductase Inhibitors with Time to Diagnosis and Mortality in Prostate Cancer.
    J Urol. 2019 Aug 12:10109701JU00005798646485082.
    PubMed    


  189. TANEJA SS
    Re: Trend of Adverse Stage Migration in Patients Treated with Radical Prostatectomy for Localized Prostate Cancer.
    J Urol. 2019 Aug 12:10109701JU000057984426332.
    PubMed    


  190. TANEJA SS
    Re: Recovery of Pad-Free Continence in Elderly Men Does Not Differ from Younger Men Undergoing Robot-Assisted Radical Prostatectomy for Aggressive Prostate Cancer.
    J Urol. 2019 Aug 12:101097JU0000000000000491. doi: 10.1097/JU.0000000000000491.
    PubMed    


  191. KAPLAN SA
    Re: Oxidative Damage in Patients with Benign Prostatic Hyperplasia and Prostate Cancer Co-Exposed to Phthalates and to Trace Elements.
    J Urol. 2019 Aug 12:10109701JU000057986087720.
    PubMed    


  192. RESNICK MJ
    Re: Association of Treatment with 5alpha-Reductase Inhibitors with Time to Diagnosis and Mortality in Prostate Cancer.
    J Urol. 2019 Aug 12:10109701JU00005798568009731.
    PubMed    


  193. XU L, Mao X, Grey A, Scandura G, et al
    Non-invasive Detection of Clinically Significant Prostate Cancer Using Circulating Tumor Cells.
    J Urol. 2019 Aug 7:101097JU0000000000000475. doi: 10.1097/JU.0000000000000475.
    PubMed     Abstract available


  194. DAL MORO F, Pizzolito S
    Re: Transperineal Prostate Biopsies Using Local Anesthesia: Experience with 1,287 Patients. Prostate Cancer Detection Rate, Complications and Patient Tolerability.
    J Urol. 2019 Aug 7:101097JU0000000000000474. doi: 10.1097/JU.0000000000000474.
    PubMed    


  195. BUCKLEY RJ
    Re: Transperineal Prostate Biopsies Using Local Anesthesia: Experience with 1,287 Patients. Prostate Cancer Detection Rate, Complications and Patient Tolerability.
    J Urol. 2019 Aug 7:101097JU0000000000000473. doi: 10.1097/JU.0000000000000473.
    PubMed    


  196. SUNDI D, Nyame YA
    Editorial Comment.
    J Urol. 2019;202:254-255.
    PubMed    


  197. MOUL JW
    Editorial Comment.
    J Urol. 2019;202:254.
    PubMed    


  198. LUIS DE CASTRO ABREU A, Jadvar H
    Editorial Comment.
    J Urol. 2019;202:420-421.
    PubMed    


  199. STONE NN, Crawford ED, Skouteris VM, Arangua P, et al
    Reply by Authors.
    J Urol. 2019;202:271.
    PubMed    


  200. PORTER CR
    Editorial Comment.
    J Urol. 2019;202:270.
    PubMed    


  201. SANCHEZ-SALAS R, Stabile A
    Editorial Comment.
    J Urol. 2019;202:270-271.
    PubMed    


  202. EGGENER S
    Editorial Comment.
    J Urol. 2019;202:263.
    PubMed    


  203. SIEGEL C
    Re: Multiparametric MRI Features and Pathologic Outcome of Wedge-Shaped Lesions in the Peripheral Zone on T2-Weighted Images of the Prostate.
    J Urol. 2019;202:190.
    PubMed    


    July 2019
  204. ATALA A
    Re: ARv7 Represses Tumor-Suppressor Genes in Castration-Resistant Prostate Cancer.
    J Urol. 2019 Jul 31:10109701JU000057944436265.
    PubMed    


  205. JACOBS BL, Yabes JG, Lopa SH, Heron DE, et al
    The Influence of Stereotactic Body Radiation Therapy Adoption on Prostate Cancer Treatment Patterns.
    J Urol. 2019 Jul 30:101097JU0000000000000471. doi: 10.1097/JU.0000000000000471.
    PubMed     Abstract available


  206. OISHI M, Gill IS, Tafuri A, Shakir A, et al
    Hemi-Gland Cryoablation for Localized Low-, Intermediate- and High-Risk Prostate Cancer: Oncologic and Functional Outcomes at 5 years.
    J Urol. 2019 Jul 26:101097JU0000000000000456. doi: 10.1097/JU.0000000000000456.
    PubMed     Abstract available


  207. TANEJA SS
    Re: Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer.
    J Urol. 2019 Jul 11:10109701JU0000577260122781.
    PubMed    


  208. TANEJA SS
    Re: Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer.
    J Urol. 2019 Jul 11:101097JU0000000000000443. doi: 10.1097/JU.0000000000000443.
    PubMed    


  209. ATALA A
    Re: The Proteogenomic Landscape of Curable Prostate Cancer.
    J Urol. 2019 Jul 9:10109701JU000057698013730.
    PubMed    


  210. SIEGEL C
    Re: PTEN Expression in Prostate Cancer: Relationship with Clinicopathologic Features and Multiparametric MRI Findings.
    J Urol. 2019 Jul 8:101097JU0000000000000428. doi: 10.1097/JU.0000000000000428.
    PubMed    


  211. WALTON-DIAZ A, Madariaga-Venegas M
    Editorial Comment.
    J Urol. 2019;202:106-107.
    PubMed    


  212. FRASER M
    Editorial Comment.
    J Urol. 2019;202:95.
    PubMed    


  213. KLEIN EA
    Editorial Comment.
    J Urol. 2019;202:101.
    PubMed    


  214. BRAVI CA, Tin A, Vertosick E, Mazzone E, et al
    The Impact of Experience on the Risk of Surgical Margins and Biochemical Recurrence after Robot-Assisted Radical Prostatectomy: A Learning Curve Study.
    J Urol. 2019;202:108-113.
    PubMed     Abstract available


    June 2019
  215. HANSON HA, Martin C, O'Neil B, Leiser CL, et al
    The Relative Importance of Race Compared to Healthcare and Social Factors in Predicting Prostate Cancer Mortality: A Random Forest Approach.
    J Urol. 2019 Jun 27:101097JU0000000000000416. doi: 10.1097/JU.0000000000000416.
    PubMed     Abstract available


  216. MANNAERTS CK, Wildeboer RR, Remmers S, van Kollenburg RAA, et al
    Multiparametric ultrasound for prostate cancer detection and localization: Correlation of B-mode, shearwave elastography and contrast-enhanced ultrasound with radical prostatectomy specimens.
    J Urol. 2019 Jun 27:101097JU0000000000000415. doi: 10.1097/JU.0000000000000415.
    PubMed     Abstract available


  217. FAROLFI A, Gafita A, Calais J, Eiber M, et al
    (68)Ga-PSMA-11 PET Detects Residual Prostate Cancer after Prostatectomy in a Multicenter Retrospective Study.
    J Urol. 2019 Jun 24:101097JU0000000000000417. doi: 10.1097/JU.0000000000000417.
    PubMed     Abstract available


  218. TANEJA SS
    Re: Prostate Cancer Genomic Classifier Relates More Strongly to Gleason Grade Group than Prostate Imaging Reporting and Data System Score in Multiparametric Prostate Magnetic Resonance Imaging-Ultrasound Fusion Targeted Biopsies.
    J Urol. 2019 Jun 24:10109701JU000056971634429.
    PubMed    


  219. RESNICK MJ
    Re: Use of Active Surveillance or Watchful Waiting for Low-Risk Prostate Cancer and Management Trends across Risk Groups in the United States, 2010-2015.
    J Urol. 2019 Jun 24:10109701JU000057441601701.
    PubMed    


  220. TANEJA SS
    Re: Use of Active Surveillance or Watchful Waiting for Low-Risk Prostate Cancer and Management Trends across Risk Groups in the United States, 2010-2015.
    J Urol. 2019 Jun 24:10109701JU00005749769074752.
    PubMed    


  221. FRIEDLANDER TW, Welty C, Anantharaman A, Schonhoft JD, et al
    Identification and Characterization of Circulating Tumor Cells in Men Who Have Undergone Prostatectomy for Clinically Localized, High - Risk Prostate Cancer.
    J Urol. 2019 Jun 19:101097JU0000000000000393. doi: 10.1097/JU.0000000000000393.
    PubMed     Abstract available


  222. LAVIANA AA, Hernandez A, Huang LC, Zhao Z, et al
    Interpretation of domain scores on the expanded prostate cancer index composite: How does the domain score translate into functional outcomes?
    J Urol. 2019 Jun 19:101097JU0000000000000392. doi: 10.1097/JU.0000000000000392.
    PubMed     Abstract available


  223. MARGEL D, Peer A, Ber Y, Shavit-Grievink L, et al
    Cardiovascular morbidity in a randomized trial comparing GnRH-agonist and GnRH-antagonist among patients with advanced prostate-cancer and pre-existing cardiovascular disease.
    J Urol. 2019 Jun 12:101097JU0000000000000384. doi: 10.1097/JU.0000000000000384.
    PubMed     Abstract available


  224. ATALA A
    Re: Inhibition of De Novo Lipogenesis Targets Androgen Receptor Signaling in Castration-Resistant Prostate Cancer.
    J Urol. 2019 Jun 10:101097JU0000000000000379. doi: 10.1097/JU.0000000000000379.
    PubMed    


  225. SIEGEL C
    Re: A Grading System for the Assessment of Risk of Extraprostatic Extension of Prostate Cancer at Multiparametric MRI.
    J Urol. 2019 Jun 5:101097JU0000000000000371. doi: 10.1097/JU.0000000000000371.
    PubMed    


  226. SHAH N, Ioffe V
    Re: Active Surveillance of Prostate Cancer is a Viable Option for Men Younger than 60 Years. Keyan Salari et al. JOU. Vol 201, 721-727, April 2019.
    J Urol. 2019 Jun 4:101097JU0000000000000362. doi: 10.1097/JU.0000000000000362.
    PubMed    


  227. SALARI K, Feldman AS
    Re: Salari et al. Active Surveillance of Prostate Cancer is a Viable Option for Men Younger than 60 Years. JUrol. Vol 201, 721-727, April 2019.
    J Urol. 2019 Jun 4:101097JU0000000000000363. doi: 10.1097/JU.0000000000000363.
    PubMed    


  228. FERNANDO H, Garcia C, Hossack T, Ahmadi N, et al
    Incidence, Predictive Factors and Preventive Measures for Inguinal Hernia following Robotic and Laparoscopic Radical Prostatectomy: A Systematic Review.
    J Urol. 2019;201:1072-1079.
    PubMed     Abstract available


  229. GRUMMET J
    Editorial Comment.
    J Urol. 2019;201:1126.
    PubMed    


  230. AYDIN AM, Pow-Sang JM
    Editorial Comment.
    J Urol. 2019;201:1125-1126.
    PubMed    


  231. CROOK J
    Editorial Comment.
    J Urol. 2019;201:1133.
    PubMed    


  232. THOMPSON JE, Sridhar AN, Tan WS, Freeman A, et al
    Pathological Findings and Magnetic Resonance Imaging Concordance at Salvage Radical Prostatectomy for Local Recurrence following Partial Ablation Using High Intensity Focused Ultrasound.
    J Urol. 2019;201:1134-1143.
    PubMed     Abstract available


    May 2019
  233. HANNA N, Wszolek MF, Mojtahed A, Nicaise E, et al
    MULTIPARAMETRIC MRI/ULTRASOUND FUSION BIOPSY IMPROVES BUT DOES NOT REPLACE STANDARD TEMPLATE BIOPSY FOR THE DETECTION OF PROSTATE CANCER.
    J Urol. 2019 May 30:101097JU0000000000000359. doi: 10.1097/JU.0000000000000359.
    PubMed     Abstract available


  234. GROSS MD, Sedrakyan A, Bianco FJ, Carroll PR, et al
    Study of Prostate Ablation Related Energy Devices (SPARED) Collaboration: Patient Selection for Partial Gland Ablation in Men with Localized Prostate Cancer.
    J Urol. 2019 May 30:101097JU0000000000000357. doi: 10.1097/JU.0000000000000357.
    PubMed     Abstract available


  235. MURALIDHAR V, Mahal BA, Butler S, Lamba N, et al
    Combined external beam radiation therapy and brachytherapy versus radical prostatectomy with adjuvant radiation therapy for Gleason 9-10 prostate cancer.
    J Urol. 2019 May 30:101097JU0000000000000352. doi: 10.1097/JU.0000000000000352.
    PubMed     Abstract available


  236. GULATI R, Psutka SP, Etzioni R
    Personalized risks of overdiagnosis for screen-detected prostate cancer incorporating patient comorbidities: Estimation and communication.
    J Urol. 2019 May 21:101097JU0000000000000346. doi: 10.1097/JU.0000000000000346.
    PubMed     Abstract available


  237. SHARMA V, Wymer KM, Borah BJ, Barocas DA, et al
    Cost-Effectiveness of Active Surveillance, Radical Prostatectomy, and External Beam Radiotherapy for Localized Prostate Cancer: An Analysis of the ProtecT Trial.
    J Urol. 2019 May 21:101097JU0000000000000345. doi: 10.1097/JU.0000000000000345.
    PubMed     Abstract available


  238. ZUNIGA KB, Zhao S, Kenfield SA, Cedars B, et al
    Trends in complementary and alternative medicine use among patients with prostate cancer.
    J Urol. 2019 May 15:101097JU0000000000000336. doi: 10.1097/JU.0000000000000336.
    PubMed     Abstract available


  239. GRIEBLING TL
    Re: Systematic Review and Network Meta-Analysis on the Relative Efficacy of Osteoporotic Medications: Men with Prostate Cancer on Continuous Androgen-Deprivation Therapy to Reduce Risk of Fragility Fractures.
    J Urol. 2019 May 10:10109701JU000055973645783.
    PubMed    


  240. GONTERO P, Marra G, Alessio P, Filippini C, et al
    Salvage radical prostatectomy for recurrent prostate cancer: morbidity and functional outcomes from a large multicenter series of open versus robotic approaches.
    J Urol. 2019 May 10:101097JU0000000000000327. doi: 10.1097/JU.0000000000000327.
    PubMed     Abstract available


  241. TANEJA SS
    Re: Radical Prostatectomy or Watchful Waiting in Prostate Cancer-29-Year Follow-up.
    J Urol. 2019 May 7:101097JU0000000000000323. doi: 10.1097/JU.0000000000000323.
    PubMed    


  242. TANEJA SS
    Re: A 17-Gene Panel for Prediction of Adverse Prostate Cancer Pathologic Features: Prospective Clinical Validation and Utility.
    J Urol. 2019 May 7:10109701JU0000559603179075.
    PubMed    


  243. ATALA A
    Re: Molecular Evolution of Early-Onset Prostate Cancer Identifies Molecular Risk Markers and Clinical Trajectories.
    J Urol. 2019 May 7:101097JU0000000000000330. doi: 10.1097/JU.0000000000000330.
    PubMed    


  244. ATALA A
    Re: Inhibition of De Novo Lipogenesis Targets Androgen Receptor Signaling in Castration-Resistant Prostate Cancer.
    J Urol. 2019 May 7:10109701JU0000559616036260.
    PubMed    


  245. TOM MC, Nguyen JK, Luciano R, Mian OY, et al
    Impact of Cribriform Pattern and Intraductal Carcinoma on Gleason 7 Prostate Cancer Treated with External Beam Radiotherapy.
    J Urol. 2019 May 6:101097JU0000000000000316. doi: 10.1097/JU.0000000000000316.
    PubMed     Abstract available


  246. MORTEZAVI A, Krauter J, Gu DA, Sonderer J, et al
    Extensive histological sampling following focal therapy of clinically significant prostate cancer with high-intensity focused ultrasound.
    J Urol. 2019 May 1:101097JU0000000000000298. doi: 10.1097/JU.0000000000000298.
    PubMed     Abstract available


  247. CARTER HB
    Editorial Comment.
    J Urol. 2019;201:922.
    PubMed    


  248. DALL'ERA M
    Editorial Comment.
    J Urol. 2019;201:935-936.
    PubMed    


  249. MOORE C
    Editorial Comment.
    J Urol. 2019;201:928.
    PubMed    


  250. SRIVASTAVA A, Joshi SS
    Editorial Comment.
    J Urol. 2019;201:949.
    PubMed    


  251. FAISAL FA, Tosoian JJ, Han M, Macura KJ, et al
    Clinical, Pathological and Oncologic Findings of Radical Prostatectomy with Extraprostatic Extension Diagnosed on Preoperative Prostate Biopsy.
    J Urol. 2019;201:937-942.
    PubMed     Abstract available


    April 2019
  252. HAESE A, Trooskens G, Steyaert S, Hessels D, et al
    Multicenter optimization and validation of a 2-gene mRNA urine test for detection of clinically significant prostate cancer prior to initial prostate biopsy.
    J Urol. 2019 Apr 26:101097JU0000000000000293. doi: 10.1097/JU.0000000000000293.
    PubMed     Abstract available


  253. JOHNSON DC, Kwok E, Ahn C, Pashchinskiy A, et al
    Financial Margins for Prostate Cancer Surgery: Quantifying the Impact of Modifiable Cost Inputs in an Episode-based Reimbursement Model.
    J Urol. 2019 Apr 22:101097JU0000000000000283. doi: 10.1097/JU.0000000000000283.
    PubMed     Abstract available


  254. DASKIVICH TJ, Thomas IC, Luu M, Shelton JB, et al
    External Validation of the Prostate Cancer-Specific Comorbidity Index (PCCI), a Claims-Based Tool for Prediction of Life Expectancy in Men with Prostate Cancer.
    J Urol. 2019 Apr 22:101097JU0000000000000287. doi: 10.1097/JU.0000000000000287.
    PubMed     Abstract available


  255. TANEJA SS
    Re: Radiotherapy to the Primary Tumour for Newly Diagnosed, Metastatic Prostate Cancer (STAMPEDE): a Randomised Controlled Phase 3 Trial.
    J Urol. 2019 Apr 8:10109701JU00005577560832916.
    PubMed    


  256. TANEJA SS
    Re: Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study.
    J Urol. 2019 Apr 8:101097JU0000000000000276. doi: 10.1097/JU.0000000000000276.
    PubMed    


  257. TEWARI AK, Taouli B
    Radiomics features measured with multiparametric MRI predict prostate cancer aggressiveness.
    J Urol. 2019 Apr 8:101097JU0000000000000272. doi: 10.1097/JU.0000000000000272.
    PubMed     Abstract available


  258. CEDARS BE, Washington SL 3rd, Cowan JE, Leapman M, et al
    STABILITY OF A 17-GENE GENOMIC PROSTATE SCORE IN SERIAL TESTING OF MEN ON ACTIVE SURVEILLANCE FOR EARLY STAGE PROSTATE CANCER.
    J Urol. 2019 Apr 8:101097JU0000000000000271. doi: 10.1097/JU.0000000000000271.
    PubMed     Abstract available


  259. SHOAG J, Liu D, Ma X, Oromendia C, et al
    MP68-12 IMPACT OF SPOP MUTATION ON PROSTATE CANCER PROGNOSIS.
    J Urol. 2019;201.
    PubMed     Abstract available


  260. SANDHU HS, Mulholland DJ
    MP68-11 IDENTIFICATION OF INTERMEDIATE CELL POPULATIONS DURING TREATMENT INDUCED LINEAGE CONVERSION TO NEUROENDOCRINE PROSTATE CANCER.
    J Urol. 2019;201.
    PubMed     Abstract available


  261. VELLKY J, Ricke W
    MP68-13 DDX3-MEDIATED TRANSLATIONAL REGULATION OF ANDROGEN RECEPTOR IN PROSTATE CANCER PROGRESSION.
    J Urol. 2019;201.
    PubMed     Abstract available


  262. FAISAL F, Alshalalfa M, Davicioni E, Karnes RJ, et al
    MP68-10 HOXB13 EXPRESSION AND ITS ROLE IN PROSTATE CANCER PROGRESSION AND NEUROENDOCRINE DIFFERENTIATION.
    J Urol. 2019;201.
    PubMed     Abstract available


  263. JAMASPISHVILI T, Patel P, Niu Y, Vidotto T, et al
    MP28-02 QUANTITATIVE MEASUREMENT OF PTEN LOSS IMPROVES RISK ASSESSMENT IN PROSTATE CANCER.
    J Urol. 2019;201.
    PubMed     Abstract available


  264. ADSHEAD J, Oldfield F, Hadaschik B, Wouter Everaerts JA, et al
    MP20-04 USABILITY AND TECHNICAL FEASIBILITY EVALUATION OF A TETHERED LAPAROSCOPIC GAMMA PROBE FOR RADIOGUIDED SURGERY IN PROSTATE CANCER: A PELVIC PHANTOM AND PORCINE MODEL STUDY.
    J Urol. 2019;201.
    PubMed     Abstract available


  265. RICHIE JP
    Re: Association between Vasectomy and Risk of Testicular Cancer: A Systematic Review and Meta-Analysis.
    J Urol. 2019;201:667-668.
    PubMed    


  266. TOSOIAN JJ, George AK
    Editorial Comment.
    J Urol. 2019;201:727.
    PubMed    


  267. HARPER BT, Dykes TE, Terris MK
    Editorial Comment.
    J Urol. 2019;201:749.
    PubMed    


  268. SAMMON J
    Editorial Comment.
    J Urol. 2019;201:733-734.
    PubMed    


  269. GRUBB R
    Editorial Comment.
    J Urol. 2019;201:740-741.
    PubMed    


  270. KEEGAN KA
    Editorial Comment.
    J Urol. 2019;201:749.
    PubMed    


  271. DASKIVICH TJ
    Editorial Comment.
    J Urol. 2019;201:733.
    PubMed    


  272. CARROLL P, Schmidt B
    Editorial Comment.
    J Urol. 2019;201:820.
    PubMed    


  273. MARTIN C, Haaland B, Tward AE, Dechet C, et al
    Describing the Spectrum of Patient Reported Outcomes after Radical Prostatectomy: Providing Information to Improve Patient Counseling and Shared Decision Making.
    J Urol. 2019;201:751-758.
    PubMed     Abstract available


    March 2019
  274. ATALA A
    Re: Alterations of Tumor Microenvironment by Nitric Oxide Impedes Castration-Resistant Prostate Cancer Growth.
    J Urol. 2019 Mar 29:101097JU0000000000000251. doi: 10.1097/JU.0000000000000251.
    PubMed    


  275. RESNICK MJ
    Re: Risk of Prostate Cancer in Men Treated with 5alpha-Reductase Inhibitors-A Large Population-Based Prospective Study.
    J Urol. 2019 Mar 29:10109701JU00005577312536940.
    PubMed    


  276. ATALA A
    Re: Targeting FOXA1-Mediated Repression of TGF-beta Signaling Suppresses Castration-Resistant Prostate Cancer Progression.
    J Urol. 2019 Mar 29:10109701JU000055773048240.
    PubMed    


  277. PAK S, Park SY, Shin TJ, You D, et al
    Association of muscle mass with survival after radical prostatectomy in patients with prostate cancer.
    J Urol. 2019 Mar 27:101097JU0000000000000249. doi: 10.1097/JU.0000000000000249.
    PubMed     Abstract available


  278. TANEJA SS
    Re: Detection of Individual Prostate Cancer Foci via Multiparametric Magnetic Resonance Imaging.
    J Urol. 2019 Mar 13:101097JU0000000000000231. doi: 10.1097/JU.0000000000000231.
    PubMed    


  279. AMINSHARIFI A, Simon R, Polascik TJ, Robertson CN, et al
    Evaluation and active treatment versus active surveillance of localized prostate cancer in renal transplant patients in the era of low and very low risk prostate cancer.
    J Urol. 2019 Mar 5:101097JU0000000000000207. doi: 10.1097/JU.0000000000000207.
    PubMed     Abstract available


  280. STONE NN, Crawford ED, Skouteris VM, Arangua P, et al
    The ratio of the number of biopsy specimens to prostate volume (biopsy density) > 1.5 improves the prostate cancer detection rate in men undergoing transperineal biopsy of the prostate.
    J Urol. 2019 Mar 5:101097JU0000000000000204. doi: 10.1097/JU.0000000000000204.
    PubMed     Abstract available


  281. WANG CS, Jhan JH, Li CC
    Re: Prostate Specific Antigen Density as a Predictor of Clinically Significant Prostate Cancer when the Prostate Specific Antigen is in the Diagnostic Gray Zone: .: A. Aminsharifi, L. Howard, Y. Wu, A. De Hoedt, C. Bailey, S. J. Freedland and T. J. Po
    J Urol. 2019;201:627-628.
    PubMed    


  282. MORGAN SC, Hoffman K, Loblaw DA, Buyyounouski MK, et al
    Hypofractionated Radiation Therapy for Localized Prostate Cancer: Executive Summary of an ASTRO, ASCO and AUA Evidence-Based Guideline.
    J Urol. 2019;201:528-534.
    PubMed     Abstract available


  283. BRYANT RJ, Hobbs CP, Eyre KS, Davies LC, et al
    Comparison of Prostate Biopsy with or without Prebiopsy Multiparametric Magnetic Resonance Imaging for Prostate Cancer Detection: An Observational Cohort Study.
    J Urol. 2019;201:510-519.
    PubMed     Abstract available


  284. MIRAK SA, Shakeri S, Bajgiran AM, Felker ER, et al
    Three Tesla Multiparametric Magnetic Resonance Imaging: Comparison of Performance with and without Endorectal Coil for Prostate Cancer Detection, PI-RADS version 2 Category and Staging with Whole Mount Histopathology Correlation.
    J Urol. 2019;201:496-502.
    PubMed     Abstract available


  285. LI-SHENG CHEN S, Ching-Yuan Fann J, Sipeky C, Yang TK, et al
    Risk Prediction of Prostate Cancer with Single Nucleotide Polymorphisms and Prostate Specific Antigen.
    J Urol. 2019;201:486-495.
    PubMed     Abstract available


  286. ATALA A
    Re: Large-Scale Transcriptome-Wide Association Study Identifies New Prostate Cancer Risk Regions.
    J Urol. 2019;201:447.
    PubMed    


  287. ATALA A
    Re: Diverse AR-V7 Cistromes in Castration-Resistant Prostate Cancer are Governed by HoxB13.
    J Urol. 2019;201:446-447.
    PubMed    


  288. TANEJA SS
    Re: A Multicentre Study of 5-Year Outcomes following Focal Therapy in Treating Clinically Significant Nonmetastatic Prostate Cancer.
    J Urol. 2019;201:443-444.
    PubMed    


  289. TANEJA SS
    Re: Association between Prostate Magnetic Resonance Imaging and Observation for Low-Risk Prostate Cancer.
    J Urol. 2019;201:443.
    PubMed    


  290. HELFAND BT
    Editorial Comment.
    J Urol. 2019;201:494.
    PubMed    


  291. EPSTEIN J
    Editorial Comment.
    J Urol. 2019;201:540.
    PubMed    


  292. MORASH C
    Editorial Comment.
    J Urol. 2019;201:527.
    PubMed    


  293. ABDI H, Breau RH
    Editorial Comment.
    J Urol. 2019;201:518.
    PubMed    


  294. WANG S, Siddiqui MM
    Editorial Comment.
    J Urol. 2019;201:509.
    PubMed    


    February 2019
  295. FEI B, Abiodun-Ojo OA, Akintayo AA, Akin-Akintayo O, et al
    Feasibility and Initial Results: Fluciclovine PET/Ultrasound Fusion Targeted Biopsy of Recurrent Prostate Cancer.
    J Urol. 2019 Feb 28:101097JU0000000000000200. doi: 10.1097/JU.0000000000000200.
    PubMed     Abstract available


  296. TAN N, Bavadian N, Calais J, Oyoyo U, et al
    Imaging of PSMA-targeted Radiotracers for the Detection of Prostate Cancer Biochemical Recurrence After Definitive Therapy: A Systematic Review and Meta-analysis.
    J Urol. 2019 Feb 25:101097JU0000000000000198. doi: 10.1097/JU.0000000000000198.
    PubMed     Abstract available


  297. GREENLAND NY, Zhang L, Cowan JE, Carroll PR, et al
    Correlation of a Commercial Genomic Risk Classifier with Histologic Patterns in Prostate Cancer.
    J Urol. 2019 Feb 15:101097JU0000000000000175. doi: 10.1097/JU.0000000000000175.
    PubMed     Abstract available


  298. STOVSKY M, Klein EA, Chait A, Manickam K, et al
    Clinical Validation of IsoPSA, a Single Parameter, Structure-Based Assay for Improved Detection of High-Grade Prostate Cancer.
    J Urol. 2019 Feb 15:101097JU0000000000000185. doi: 10.1097/JU.0000000000000185.
    PubMed     Abstract available


  299. ECHEVARRIA MI, Awasthi S, Cheng CH, Berglund AE, et al
    African American Specific Gene Panel Predictive of Poor Prostate Cancer Outcome.
    J Urol. 2019 Feb 15:101097JU0000000000000193. doi: 10.1097/JU.0000000000000193.
    PubMed     Abstract available


  300. GAFFNEY C, Golan R, Cantu MD, Scognamiglio T, et al
    The Clinical Utility of the Genomic Prostate Score in Men with Very Low to Intermediate Risk Prostate Cancer.
    J Urol. 2019 Feb 12:101097JU0000000000000170. doi: 10.1097/JU.0000000000000170.
    PubMed     Abstract available


  301. TANEJA SS
    Re: Randomized Trial of Hypofractionated, Dose-Escalated, Intensity-Modulated Radiation Therapy (IMRT) versus Conventionally Fractionated IMRT for Localized Prostate Cancer.
    J Urol. 2019 Feb 8. doi: 10.1097/JU.0000000000000169.
    PubMed    


  302. TANEJA SS
    Re: Germline Mutations in ATM and BRCA1/2 Are Associated with Grade Reclassification in Men on Active Surveillance for Prostate Cancer.
    J Urol. 2019 Feb 8. doi: 10.1097/01.JU.0000554059.66296.
    PubMed    


  303. STEFANOVA V, Buckley R, Flax S, Spevack L, et al
    Transperineal prostate biopsies under local anesthetic: Experience with 1287 patients Prostate cancer detection rate, complications and patient tolerability.
    J Urol. 2019 Feb 8:101097JU0000000000000156. doi: 10.1097/JU.0000000000000156.
    PubMed     Abstract available


  304. DAMODARAN S, Lang JM, Jarrard DF
    Targeting Metastatic Hormone Sensitive Prostate Cancer: Chemohormonal Therapy and New Combinatorial Approaches.
    J Urol. 2019 Feb 7. doi: 10.1097/JU.0000000000000117.
    PubMed     Abstract available


  305. ATALA A
    Re: Classification of Prostate Cancer Using a Protease Activity Nanosensor Library.
    J Urol. 2019 Feb 7. doi: 10.1097/01.JU.0000554005.76376.
    PubMed    


  306. ATALA A
    Re: Immunogenomic Analyses Associate Immunological Alterations with Mismatch Repair Defects in Prostate Cancer.
    J Urol. 2019 Feb 7. doi: 10.1097/01.JU.0000554004.38258.
    PubMed    


  307. GRIEBLING TL
    Re: Localised Prostate Cancer in Elderly Men Aged 80-89 Years, Findings from a Population-Based Registry.
    J Urol. 2019 Feb 7. doi: 10.1097/01.JU.0000553998.44096.
    PubMed    


  308. GRIEBLING TL
    Re: Alzheimer's Disease is Associated with Prostate Cancer: .
    J Urol. 2019 Feb 7. doi: 10.1097/01.JU.0000553997.66966.
    PubMed    


  309. DAS S, Salami SS, Spratt DE, Kaffenberger SD, et al
    Bringing prostate cancer germline genetics into clinical practice.
    J Urol. 2019 Feb 5. doi: 10.1097/JU.0000000000000137.
    PubMed     Abstract available


  310. ZELEFSKY MJ, Goldman DA, Reuter V, Kollmeier M, et al
    Long-Term Implications of a Positive Post Treatment Biopsy Among Patients Treated with External Beam Radiotherapy for Clinically Localized Prostate Cancer.
    J Urol. 2019 Feb 5. doi: 10.1097/JU.0000000000000110.
    PubMed     Abstract available


  311. FALAGARIO UG, Beksac AT, Martini A, Cumarasamy S, et al
    Defining Prostate Cancer at Favorable Intermediate Risk: the Potential Utility Of Magnetic Resonance Imaging And Genomic Tests.
    J Urol. 2019 Feb 4. doi: 10.1097/JU.0000000000000134.
    PubMed     Abstract available


  312. ATALA A
    Re: TRAF4-Mediated Ubiquitination of NGF Receptor TrkA Regulates Prostate Cancer Metastasis.
    J Urol. 2019;201:230.
    PubMed    


  313. ATALA A
    Re: A Somatically Acquired Enhancer of the Androgen Receptor is a Noncoding Driver in Advanced Prostate Cancer.
    J Urol. 2019;201:230.
    PubMed    


  314. TANEJA SS
    Re: Role of the 4Kscore Test as a Predictor of Reclassification in Prostate Cancer Active Surveillance.
    J Urol. 2019;201:228.
    PubMed    


  315. TANEJA SS
    Re: Histologic Findings Associated with False Positive Multiparametric Magnetic Resonance Imaging Performed for Prostate Cancer Detection.
    J Urol. 2019;201:227-228.
    PubMed    


  316. SIEGEL C
    Re: Validation of PI-RADS Version 2 in Transition Zone Lesions for the Detection of Prostate Cancer.
    J Urol. 2019;201:208.
    PubMed    


  317. TILKI D
    Editorial Comment.
    J Urol. 2019;201:340.
    PubMed    


  318. SCARSBROOK A
    Editorial Comment.
    J Urol. 2019;201:331.
    PubMed    


  319. BREAU RH, Kumar R
    Editorial Comment.
    J Urol. 2019;201:331.
    PubMed    


  320. THOMPSON JE, Stricker PD
    Editorial Comment.
    J Urol. 2019;201:306-307.
    PubMed    


  321. CARROLL P
    Editorial Comment.
    J Urol. 2019;201:298-299.
    PubMed    


  322. CHUA MLK
    Editorial Comment.
    J Urol. 2019;201:291.
    PubMed    


  323. BREAU RH, Kumar R
    Editorial Comment.
    J Urol. 2019;201:290-291.
    PubMed    


  324. WANG S, Siddiqui MM
    Editorial Comment.
    J Urol. 2019;201:277.
    PubMed    


  325. GRUMMET J
    Editorial Comment.
    J Urol. 2019;201:276.
    PubMed    


  326. MOSES KA
    Editorial Comment.
    J Urol. 2019;201:267.
    PubMed    


  327. EGGENER S
    Editorial Comment.
    J Urol. 2019;201:266-267.
    PubMed    


  328. PIERRARD V, Lebdai S, Kleinclauss F, Azzouzi AR, et al
    Radical Prostatectomy after Vascular Targeted Photodynamic Therapy with Padeliporfin: Feasibility, and Early and Intermediate Results.
    J Urol. 2019;201:315-321.
    PubMed     Abstract available


  329. KIRMIZ S, Qi J, Babitz SK, Linsell S, et al
    Grade Groups Provide Improved Predictions of Pathological and Early Oncologic Outcomes Compared with Gleason Score Risk Groups.
    J Urol. 2019;201:278-283.
    PubMed     Abstract available


    January 2019
  330. BOTEJUE M, Abbott D, Danella J, Fonshell C, et al
    Utilization of Active Surveillance as Initial Management of Newly Diagnosed Prostate Cancer: Data from the PURC.
    J Urol. 2019 Jan 31. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


  331. BURNS JF, Hurwitz LM, Levie KE, Caumont F, et al
    Impact of Subsequent Biopsies on Comprehensive Health Related Quality of Life in Patients With and Without Prostate Cancer.
    J Urol. 2019 Jan 25. doi: 10.1097/JU.0000000000000024.
    PubMed     Abstract available


  332. GINSBURG KB, Arcot R, Qi J, Linsell SM, et al
    Confirmatory MRI With or Without Biopsy Impacts Decision-Making in Newly Diagnosed Favorable Risk Prostate Cancer.
    J Urol. 2019 Jan 25. doi: 10.1097/JU.0000000000000059.
    PubMed     Abstract available


  333. GOLD SA, Shih JH, Rais-Bahrami S, Bloom JB, et al
    When to Biopsy the Seminal Vesicles: A Validated Multiparametric Magnetic Resonance Imaging and Target Driven Model to Detect Seminal Vesicle Invasion in Prostate Cancer.
    J Urol. 2019 Jan 23. doi: 10.1097/JU.0000000000000112.
    PubMed     Abstract available


  334. YAXLEY JW, Raveenthiran S, Nouhaud FX, Samartunga H, et al
    Outcomes of Primary Lymph Node Staging of Intermediate and High Risk Prostate Cancer with 68Ga-PSMA Positron Emission Tomography/Computerized Tomography Compared to Histological Correlation of Pelvic Lymph Node Pathology: Can Preoperative 68Ga-PSMA Po
    J Urol. 2019 Jan 21. doi: 10.1097/JU.0000000000000053.
    PubMed     Abstract available


  335. SALARI K, Kuppermann D, Preston MA, Dahl DM, et al
    Active Surveillance of Prostate Cancer is a Viable Option in Men Younger Than 60 Years.
    J Urol. 2019 Jan 16. doi: 10.1097/JU.0000000000000031.
    PubMed     Abstract available


  336. TANEJA SS
    Re: Transcriptomic Heterogeneity in Multifocal Prostate Cancer.
    J Urol. 2019 Jan 15. doi: 10.1097/JU.0000000000000101.
    PubMed    


  337. TANEJA SS
    Re: Olaparib Combined with Abiraterone in Patients with Metastatic Castration-Resistant Prostate Cancer: .
    J Urol. 2019 Jan 15. doi: 10.1097/01.JU.0000553310.60445.
    PubMed    


  338. ATALA A
    Re: Nuclear Pores Promote Lethal Prostate Cancer by Increasing POM121-Driven E2F1, MYC, and AR Nuclear Import.
    J Urol. 2019 Jan 15. doi: 10.1097/JU.0000000000000096.
    PubMed    


  339. ZHAO J, Liu J, Sun G, Zhang M, et al
    The Prognostic Value of the Proportion and Architectural Patterns of Intraductal Carcinoma of the Prostate in Patients with de Novo Metastatic Prostate Cancer.
    J Urol. 2019 Jan 15. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


  340. HUANG H, Muscatelli S, Naslund M, Badiyan SN, et al
    Evaluation of Cancer Specific Mortality with Surgery versus Radiation as Primary Therapy for Localized High Grade Prostate Cancer in Men Younger Than 60 Years.
    J Urol. 2019;201:120-128.
    PubMed     Abstract available


  341. BASS R, Fleshner N, Finelli A, Barkin J, et al
    Oncologic and Functional Outcomes of Partial Gland Ablation with High Intensity Focused Ultrasound for Localized Prostate Cancer.
    J Urol. 2019;201:113-119.
    PubMed     Abstract available


  342. FAIENA I, Salmasi A, Mendhiratta N, Markovic D, et al
    PI-RADS Version 2 Category on 3 Tesla Multiparametric Prostate Magnetic Resonance Imaging Predicts Oncologic Outcomes in Gleason 3 + 4 Prostate Cancer on Biopsy.
    J Urol. 2019;201:91-97.
    PubMed     Abstract available


  343. BLOOM JB, Hale GR, Gold SA, Rayn KN, et al
    Predicting Gleason Group Progression for Men on Prostate Cancer Active Surveillance: Role of a Negative Confirmatory Magnetic Resonance Imaging-Ultrasound Fusion Biopsy.
    J Urol. 2019;201:84-90.
    PubMed     Abstract available


  344. ATALA A
    Re: Diverse AR-V7 Cistromes in Castration-Resistant Prostate Cancer are Governed by HoxB13.
    J Urol. 2019;201:33-34.
    PubMed    


  345. ATALA A
    Re: Acquisition of Tumorigenic Potential and Therapeutic Resistance in CD133+ Subpopulation of Prostate Cancer Cells Exhibiting Stem-Cell Like Characteristics.
    J Urol. 2019;201:33.
    PubMed    


  346. TANEJA SS
    Re: Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer.
    J Urol. 2019;201:31.
    PubMed    


  347. CATHELINEAU X, Sanchez-Salas R
    Editorial Comment.
    J Urol. 2019;201:119.
    PubMed    


  348. STERNBERG IA
    Editorial Comment.
    J Urol. 2019;201:104.
    PubMed    


  349. DASKIVICH TJ
    Editorial Comment.
    J Urol. 2019;201:104.
    PubMed    


  350. GLASER ZA, Rais-Bahrami S
    Editorial Comment.
    J Urol. 2019;201:90.
    PubMed    


  351. PUNNEN S
    Editorial Comment.
    J Urol. 2019;201:83.
    PubMed    


  352. PERLIS N
    Editorial Comment.
    J Urol. 2019;201:82.
    PubMed    


  353. SIVARAMAN A, Kim EH, Andriole GL
    Editorial Comment.
    J Urol. 2019;201:112.
    PubMed    


    December 2018
  354. FRIEDLANDER DF, von Landenberg N, Loppenberg B, Noldus J, et al
    Facility-Level Variation In Rates Of Definitive Therapy For Low-Risk Prostate Cancer Among Men With Limited Life Expectancy: An Opportunity For Value-Based Care Redesign.
    J Urol. 2018 Dec 24. doi: 10.1097/JU.0000000000000006.
    PubMed     Abstract available


  355. BEKSAC AT, Cumarasamy S, Falagario U, Xu P, et al
    Multiparametric Magnetic Resonance Imaging Features Identify Aggressive Prostate Cancer at the Phenotypic and Transcriptomic Level.
    J Urol. 2018;200:1241-1249.
    PubMed     Abstract available


    November 2018
  356. KRIMPHOVE MJ, Fletcher SA, Cole AP, Berg S, et al
    Quality of Care in the Treatment of Localized Intermediate and High Risk Prostate Cancer at Minority Serving Hospitals.
    J Urol. 2018 Nov 8. pii: S0022-5347(18)44053-0. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


  357. TANEJA SS
    Re: Effects of Pathological Upstaging or Upgrading on Metastasis and Cancer-Specific Mortality in Men with Clinical Low-Risk Prostate Cancer.
    J Urol. 2018;200:945-946.
    PubMed    


  358. TANEJA SS
    Re: Germline DNA-Repair Gene Mutations and Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer Receiving First-Line Abiraterone and Enzalutamide.
    J Urol. 2018;200:945.
    PubMed    


  359. TANEJA SS
    Re: Circulating microRNAs and Treatment Response in the Phase II SWOG S0925 Study for Patients with New Metastatic Hormone-Sensitive Prostate Cancer.
    J Urol. 2018;200:944-946.
    PubMed    


  360. RESNICK MJ
    Re: Quality of Life during Treatment with Chemohormonal Therapy: Analysis of E3805 Chemohormonal Androgen Ablation Randomized Trial in Prostate Cancer.
    J Urol. 2018;200:936.
    PubMed    


    October 2018
  361. CHEN SL, Fann JC, Sipeky C, Yang TK, et al
    Risk Prediction of Prostate Cancer with Single Nucleotide Polymorphisms (SNPs) and Prostate-Specific Antigen (PSA).
    J Urol. 2018 Oct 23. pii: S0022-5347(18)44024-4. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


  362. ETHERIDGE T, Liou JI, Downs TM, Abel EJ, et al
    The Impact of Agent Orange Exposure on Prostate Cancer Outcomes.
    J Urol. 2018 Oct 12. pii: S0022-5347(18)43983-3. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


  363. WALTON E, Yaguchi G, Keeley J, Deebajah M, et al
    Effect of Lesion Location on Prostate Cancer Detection Rate with Magnetic Resonance Imaging Targeted Biopsy in African Americans.
    J Urol. 2018 Oct 11. pii: S0022-5347(18)43980-8. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


  364. MORGAN SC, Hoffman K, Loblaw DA, Buyyounouski MK, et al
    Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline.
    J Urol. 2018 Oct 9. pii: S0022-5347(18)43963-8. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


  365. ITO Y, Udo K, Vertosick EA, Sjoberg DD, et al
    Clinical Utility of Prostate and Tumor Volume-Related Parameters Following Radical Prostatectomy for Localized Prostate Cancer.
    J Urol. 2018 Oct 6. pii: S0022-5347(18)43967-5. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


  366. ATALA A
    Re: Compartmentalized Activities of the Pyruvate Dehydrogenase Complex Sustain Lipogenesis in Prostate Cancer.
    J Urol. 2018;200:701-702.
    PubMed    


  367. TANEJA SS
    Re: Effect of a Low-Intensity PSA-Based Screening Intervention on Prostate Cancer Mortality: The CAP Randomized Clinical Trial.
    J Urol. 2018;200:699.
    PubMed    


  368. TANEJA SS
    Re: Short-Term Effects of Transdermal Estradiol in Men Undergoing Androgen Deprivation Therapy for Prostate Cancer: A Randomized Placebo-Controlled Trial.
    J Urol. 2018;200:698-699.
    PubMed    


  369. TANEJA SS
    Re: MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis.
    J Urol. 2018;200:697-699.
    PubMed    


  370. RESNICK MJ
    Re: Using Medicare Claims to Examine Long-Term Prostate Cancer Risk of Finasteride in the Prostate Cancer Prevention Trial.
    J Urol. 2018;200:689.
    PubMed    


    September 2018
  371. AFSHARI MIRAK S, Shakeri S, Mohammadian Bajgiran A, Felker ER, et al
    3T Multiparametric MRI: Comparison of Performance With and Without Endorectal Coil for Prostate Cancer Detection, PI-RADSv2 Category and Staging with Whole Mount Histopathology Correlation in 429 Patients.
    J Urol. 2018 Sep 28. pii: S0022-5347(18)43960-2. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


  372. BRYANT RJ, Hobbs CP, Eyre KS, Davies LC, et al
    Comparison of prostate biopsy with or without pre-biopsy multi-parametric MRI in prostate cancer detection: an observational cohort study.
    J Urol. 2018 Sep 25. pii: S0022-5347(18)43943-2. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


  373. THOMSEN FB, Jakobsen H, Langkilde NC, Borre M, et al
    Active surveillance for localized prostate cancer. Nationwide, observational study.
    J Urol. 2018 Sep 18. pii: S0022-5347(18)43911-0. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


  374. LOEB S, Folkvaljon Y, Bratt O, Robinson D, et al
    Defining Intermediate-Risk Prostate Cancer Suitable for Active Surveillance.
    J Urol. 2018 Sep 18. pii: S0022-5347(18)43908-0. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


  375. BALAKRISHNAN AS, Palmer NR, Fergus KB, Gaither TW, et al
    Minority recruitment trends in phase III prostate cancer clinical trials (2003-2014): progress and critical areas for improvement.
    J Urol. 2018 Sep 12. pii: S0022-5347(18)43872-4. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


  376. RAJARUBENDRA N, Almeida F, Manojlovic Z, Ohe C, et al
    Histologic Validation of (11)Carbon-Acetate Positron Emission Tomography/Computer Tomography in Detecting Lymph Node Metastases in Prostate Cancer.
    J Urol. 2018 Sep 12. pii: S0022-5347(18)43871-2. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


  377. OISHI M, Shin T, Ohe C, Nassiri N, et al
    Which Patients with Negative Magnetic Resonance Imaging Can Safely Avoid Biopsy for Prostate Cancer?
    J Urol. 2018 Sep 3. pii: S0022-5347(18)43794-9. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


  378. KORNBERG Z, Cowan JE, Westphalen AC, Cooperberg MR, et al
    Genomic Prostate Score, PI-RADSv2, and Progression in Men with Prostate Cancer on Active Surveillance.
    J Urol. 2018 Sep 1. pii: S0022-5347(18)43795-0. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


  379. ANDRIOLE GL, Kostakoglu L, Chau A, Duan F, et al
    The Impact of Positron Emission Tomography with (18)F-Fluciclovine on the Management of Patients with Biochemical Recurrence of Prostate Cancer: Results from the LOCATE Trial.
    J Urol. 2018 Sep 1. pii: S0022-5347(18)43798-6. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


  380. GREGG JR, Lopez DS, Reichard C, Zheng J, et al
    Coffee, Caffeine Metabolism Genotype, and Disease Progression in Localized Prostate Cancer Patients Managed with Active Surveillance.
    J Urol. 2018 Sep 1. pii: S0022-5347(18)43796-2. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


  381. ATALA A
    Re: An Aberrant SREBP-Dependent Lipogenic Program Promotes Metastatic Prostate Cancer.
    J Urol. 2018;200:501-502.
    PubMed    


  382. TANEJA SS
    Re: Validation of the 2015 Prostate Cancer Grade Groups for Predicting Long-Term Oncologic Outcomes in a Shared Equal-Access Health System.
    J Urol. 2018;200:499.
    PubMed    


  383. TANEJA SS
    Re: Development and Validation of a Novel Integrated Clinical-Genomic Risk Group Classification for Localized Prostate Cancer.
    J Urol. 2018;200:498-499.
    PubMed    


  384. TANEJA SS
    Re: Comparison between Adjuvant and Early-Salvage Postprostatectomy Radiotherapy for Prostate Cancer with Adverse Pathological Features.
    J Urol. 2018;200:497-499.
    PubMed    


  385. RESNICK MJ
    Re: Comparative Analysis of Biopsy Upgrading in Four Prostate Cancer Active Surveillance Cohorts.
    J Urol. 2018;200:488-489.
    PubMed    


  386. BOEHM K
    Editorial Comment.
    J Urol. 2018;200:557.
    PubMed    


  387. BARR RG
    Editorial Comment.
    J Urol. 2018;200:557-558.
    PubMed    


  388. MARKS LS
    Editorial Comment.
    J Urol. 2018;200:563.
    PubMed    


  389. LUDVIGSON A, Sammon J
    Editorial Comment.
    J Urol. 2018;200:581.
    PubMed    


  390. PINTHUS JH
    Editorial Comment.
    J Urol. 2018;200:580.
    PubMed    


  391. XU AJ, Taksler GB, Llukani E, Lepor H, et al
    Long-Term Continence Outcomes in Men Undergoing Radical Prostatectomy: A Prospective 15-Year Longitudinal Study.
    J Urol. 2018;200:626-632.
    PubMed     Abstract available


  392. BABALOLA O, Lee TJ, Viviano CJ
    Prostate Ablation Using High Intensity Focused Ultrasound: A Literature Review of the Potential Role for Patient Preference Information.
    J Urol. 2018;200:512-519.
    PubMed     Abstract available


  393. GUO DP, Thomas IC, Mittakanti HR, Shelton JB, et al
    The Research Implications of Prostate Specific Antigen Registry Errors: Data from the Veterans Health Administration.
    J Urol. 2018;200:541-548.
    PubMed     Abstract available


    August 2018
  394. BERLIN A, Moraes FY, Sanmamed N, Glicksman R, et al
    International multi-center validation of an intermediate-risk subclassification of prostate cancer treated with radical treatment without hormone therapy.
    J Urol. 2018 Aug 25. pii: S0022-5347(18)43782-2. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


  395. FAIENA I, Salmasi A, Mendhiratta N, Markovic D, et al
    PI-RADSv2 Category on 3 Tesla Multiparametric Prostate MRI Predicts Oncologic Outcomes in Gleason 3+4 Prostate Cancer on Biopsy.
    J Urol. 2018 Aug 21. pii: S0022-5347(18)43729-9. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


  396. LOUGHLIN KR
    Serum Testosterone Levels and Prostate Cancer Risk: A Single Post-Hoc Testosterone Measurement is not Informative.
    J Urol. 2018 Aug 18. pii: S0022-5347(18)43724-X. doi: 10.1016/j.juro.2018.
    PubMed    


  397. DRUSKIN SC, Mamawala M, Tosoian JJ, Epstein JI, et al
    Older Age Predicts Biopsy and Radical Prostatectomy Grade Reclassification to Aggressive Prostate Cancer in Men on Active Surveillance.
    J Urol. 2018 Aug 13. pii: S0022-5347(18)43703-2. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


  398. LOWRANCE WT, Murad MH, Oh WK, Jarrard DF, et al
    Castration-Resistant Prostate Cancer: AUA Guideline Amendment 2018.
    J Urol. 2018 Aug 4. pii: S0022-5347(18)43671-3. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


  399. CRAWFORD ED, Koo PJ, Shore N, Slovin SF, et al
    A Clinician's Guide to Next Generation Imaging in Patients With Advanced Prostate Cancer (Prostate Cancer Radiographic Assessments for Detection of Advanced Recurrence [RADAR] III).
    J Urol. 2018 Aug 2. pii: S0022-5347(18)43643-9. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


  400. DEAN LW, Assel M, Sjoberg DD, Vickers AJ, et al
    Clinical utility of total length Gleason pattern 4 on biopsy in men with Grade Group 2 prostate cancer.
    J Urol. 2018 Aug 1. pii: S0022-5347(18)43632-4. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


  401. KEARNS JT, Faino AV, Schenk JM, Newcomb LF, et al
    Continued Five-Alpha Reductase Inhibitor Use After Prostate Cancer Diagnosis and the Risk of Reclassification and Adverse Pathological Outcomes in the Canary Prostate Active Surveillance Study (PASS).
    J Urol. 2018 Aug 1. pii: S0022-5347(18)43635-X. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


  402. WINQUIST E
    Editorial Comment.
    J Urol. 2018;200:351-352.
    PubMed    


  403. SAAD F
    Editorial Comment.
    J Urol. 2018;200:352.
    PubMed    


  404. STATTIN P
    Editorial Comment.
    J Urol. 2018;200:325-326.
    PubMed    


  405. LEHRER S
    Editorial Comment.
    J Urol. 2018;200:334.
    PubMed    


  406. WANG NN, Sonn GA
    Editorial Comment.
    J Urol. 2018;200:318.
    PubMed    


  407. DOMINGUEZ-ESCRIG JL
    Editorial Comment.
    J Urol. 2018;200:317-318.
    PubMed    


  408. CRAWFORD ED
    Editorial Comment.
    J Urol. 2018;200:343.
    PubMed    


  409. JIANG P, Liss MA, Szabo RJ
    Targeted Antimicrobial Prophylaxis Does Not Always Prevent Sepsis after Transrectal Prostate Biopsy.
    J Urol. 2018;200:361-368.
    PubMed     Abstract available


    July 2018
  410. BLOOM JB, Hale G, Gold SA, Rayn K, et al
    Predicting Gleason Group Progression for Men on Prostate Cancer Active Surveillance: The Role of a Negative Confirmatory MRI-US Fusion Biopsy.
    J Urol. 2018 Jul 28. pii: S0022-5347(18)43606-3. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


  411. HUANG H, Muscatelli S, Naslund M, Badiyan SN, et al
    Evaluation of Cancer-Specific Mortality with Surgery Versus Radiation as Primary Therapy for Localized High-Grade Prostate Cancer in Men Younger than 60 Years Old.
    J Urol. 2018 Jul 27. pii: S0022-5347(18)43599-9. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


  412. BASS R, Fleshner N, Finelli A, Barkin J, et al
    Oncologic and functional outcome of partial gland ablation with HIFU for localized prostate cancer.
    J Urol. 2018 Jul 20. pii: S0022-5347(18)43550-1. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


  413. GOVERS T, Caba L, Resnick MJ
    Cost-Effectiveness of SelectMDx in Prostate Cancer Risk Assessment.
    J Urol. 2018 Jul 13. pii: S0022-5347(18)43530-6. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


  414. TRUONG M
    Editorial Comment.
    J Urol. 2018;200:113.
    PubMed    


  415. CARLSSON S
    Editorial Comment.
    J Urol. 2018;200:87.
    PubMed    


  416. RESNICK MJ
    Editorial Comment.
    J Urol. 2018;200:80-81.
    PubMed    


  417. HUEN KH, Bergman J
    Editorial Comment.
    J Urol. 2018;200:80.
    PubMed    


  418. ROSENKRANTZ AB, Hemingway J, Hughes DR, Duszak R Jr, et al
    Evolving Use of Prebiopsy Prostate Magnetic Resonance Imaging in the Medicare Population.
    J Urol. 2018;200:89-94.
    PubMed     Abstract available


  419. GORDETSKY JB, Rais-Bahrami S
    Editorial Comment.
    J Urol. 2018;200:112-113.
    PubMed    


  420. BHINDI B, Wallis CJD
    Editorial Comment.
    J Urol. 2018;200:125.
    PubMed    


  421. BAYNE CE
    Re: Missed Opportunities to Decrease Radiation Exposure in Children with Renal Trauma: T. W. Gaither, M. A. Awad, N. V. Leva, G. P. Murphy, B. N. Breyer and H. L. Copp J Urol 2018;199:552-557.
    J Urol. 2018;200:205-206.
    PubMed    


  422. SCIALPI M, D'Andrea A, Aisa MC, Malaspina CM, et al
    Re: Risk Stratification of Equivocal Lesions on Multiparametric Magnetic Resonance Imaging of the Prostate: T. Ullrich, M. Quentin, C. Arsov, A. K. Schmaltz, A. Tschischka, N. Laqua, A. Hiester, D. Blondin, R. Rabenalt, P. Albers, G. Antoch and L. Sch
    J Urol. 2018;200:202-204.
    PubMed    


    June 2018
  423. RICHARDS KA, Liou JI, Cryns VL, Downs TM, et al
    Metformin Use Is Associated with Improved Survival in Patients with Advanced Prostate Cancer on Androgen Deprivation Therapy.
    J Urol. 2018 Jun 22. pii: S0022-5347(18)43412-X. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


  424. LEYH-BANNURAH SR, Kachanov M, Beyersdorff D, Preisser F, et al
    Anterior localization of prostate cancer suspicious MRI lesions in patients undergoing initial and repeat biopsy: Results from 1,161 patients undergoing MRI/ultrasound fusion-guided targeted biopsies.
    J Urol. 2018 Jun 20. pii: S0022-5347(18)43405-2. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


  425. MARZOUK K, Assel M, Ehdaie B, Vickers A, et al
    Long term cancer-specific anxiety in men undergoing active surveillance for prostate cancer: findings from a large prospective cohort.
    J Urol. 2018 Jun 7. pii: S0022-5347(18)43349-6. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


  426. LEPPERT JT, Asch SM, Bergman J
    Ethical Pitfalls When Estimating Life Expectancy For Patients with Prostate Cancer.
    J Urol. 2018 Jun 6. pii: S0022-5347(18)43328-9. doi: 10.1016/j.juro.2018.
    PubMed    


  427. TANEJA SS
    Re: Optimising the Diagnosis of Prostate Cancer in the Era of Multiparametric Magnetic Resonance Imaging: A Cost-Effectiveness Analysis Based on the Prostate MR Imaging Study (PROMIS).
    J Urol. 2018;199:1397-1398.
    PubMed    


  428. TANEJA SS
    Re: Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer.
    J Urol. 2018;199:1396-1398.
    PubMed    


  429. GRIEBLING TL
    Re: Potential Overtreatment among Men Aged 80 Years and Older with Localized Prostate Cancer in Japan.
    J Urol. 2018;199:1375.
    PubMed    


  430. GRIEBLING TL
    Re: Safety and Feasibility of Robot-Assisted Radical Prostatectomy for Clinically Localized Prostate Cancer in Elderly Japanese Patients.
    J Urol. 2018;199:1375-1376.
    PubMed    


  431. GRIEBLING TL
    Re: Long-Term Survival of Patients Aged 80 Years or Older Treated with Radical Prostatectomy for Prostate Cancer.
    J Urol. 2018;199:1374.
    PubMed    


  432. GRIEBLING TL
    Re: Management of Prostate Cancer in Elderly Patients: Recommendations of a Task Force of the International Society of Geriatric Oncology.
    J Urol. 2018;199:1373-1376.
    PubMed    


  433. GILL IS, Azzouzi AR, Emberton M, Coleman JA, et al
    Randomized Trial of Partial Gland Ablation with Vascular-Targeted Phototherapy versus Active Surveillance for Low-risk Prostate Cancer: Extended Follow-up and Analyses of Effectiveness.
    J Urol. 2018 Jun 1. pii: S0022-5347(18)43299-5. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


    May 2018
  434. RAYN KN, Bloom JB, Gold SA, Hale GR, et al
    Added Value of Multiparametric Magnetic Resonance Imaging to Clinical Nomograms in Predicting Adverse Pathology in Prostate Cancer.
    J Urol. 2018 May 28. pii: S0022-5347(18)43271-5. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


  435. WEINER AB, Tsai KP, Keeter MK, Victorson DE, et al
    The Influence of decision aids on prostate cancer screening preferences: A randomized survey study.
    J Urol. 2018 May 28. pii: S0022-5347(18)43270-3. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


  436. AMINSHARIFI A, Howard L, Wu Y, De Hoedt A, et al
    Prostate-specific antigen density as a predictor of clinically significant prostate cancer when the PSA level is in the diagnostic "grey-zone": Defining the optimum cut-point stratified by race and body mass index.
    J Urol. 2018 May 11. pii: S0022-5347(18)43126-6. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


  437. HOFBAUER SL, Kittner B, Maxeiner A, Heckmann R, et al
    Validation of PI-RADS version 2 for the detection of prostate cancer.
    J Urol. 2018 May 4. pii: S0022-5347(18)43099-6. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


  438. CRAWFORD ED, Schellhammer PF, McLeod DG, Moul JW, et al
    Androgen Receptor-Targeted Treatments for Prostate Cancer: 35 Years' Progress with Antiandrogens.
    J Urol. 2018 May 3. pii: S0022-5347(18)43086-8. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


  439. TANEJA SS
    Re: Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair-Deficient Prostate Cancer.
    J Urol. 2018;199:1113.
    PubMed    


  440. TANEJA SS
    Re: Comparative Analysis of Biopsy Upgrading in Four Prostate Cancer Active Surveillance Cohorts.
    J Urol. 2018;199:1112-1113.
    PubMed    


  441. SIEGEL C
    Re: Role of MRI in the Use of an Absorbable Hydrogel Spacer in Men Undergoing Radiation Therapy for Prostate Cancer: What the Radiologist Needs to Know.
    J Urol. 2018;199:1092.
    PubMed    


    April 2018
  442. RAVI P, Karnes RJ, Rangel LJ, Pagliaro LC, et al
    Outcomes and Prognostic Factors in Men Receiving Androgen Deprivation Therapy for Prostate Cancer Recurrence after Radical Prostatectomy.
    J Urol. 2018 Apr 27. pii: S0022-5347(18)43071-6. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


  443. LARSEN LK, Jakobsen JS, Abdul-Al A, Guldberg P, et al
    Noninvasive detection of high-grade prostate cancer by DNA-methylation analysis of urine cells captured by microfiltration.
    J Urol. 2018 Apr 24. pii: S0022-5347(18)43047-9. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


  444. PATEL HD, Gupta M, Tosoian JJ, Carter HB, et al
    Subtyping the Risk of Intermediate-Risk Prostate Cancer for Active Surveillance Based on Adverse Pathology at Radical Prostatectomy.
    J Urol. 2018 Apr 16. pii: S0022-5347(18)42985-0. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


  445. GILD P, Cole AP, Krasnova A, Dickerman BA, et al
    Liver Disease in Men Undergoing Androgen Deprivation Therapy for Prostate Cancer.
    J Urol. 2018 Apr 16. pii: S0022-5347(18)42984-9. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


  446. RYAN CJ, Crawford ED, Shore ND, Underwood W 3rd, et al
    The IMAAGEN Study: Effect of Abiraterone Acetate and Prednisone on Prostate-Specific Antigen and Radiographic Disease Progression in Patients with Non-Metastatic Castration-Resistant Prostate Cancer.
    J Urol. 2018 Apr 6. pii: S0022-5347(18)42900-X. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


  447. ATALA A
    Re: Prostate Cancer-Associated SPOP Mutations Confer Resistance to BET Inhibitors through Stabilization of BRD4.
    J Urol. 2018;199:895-896.
    PubMed    


  448. TANEJA SS
    Re: Cabazitaxel versus Docetaxel as First-Line Therapy for Patients with Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA.
    J Urol. 2018;199:893-894.
    PubMed    


  449. TANEJA SS
    Re: Health-Related Quality of Life for Immediate versus Delayed Androgen-Deprivation Therapy in Patients with Asymptomatic, Non-Curable Prostate Cancer (TROG 03.06 and VCOG PR 01-03 [TOAD]): A Randomised, Multicentre, Non-Blinded, Phase 3 Trial.
    J Urol. 2018;199:892-894.
    PubMed    


  450. CADEDDU JA
    Re: Robotic Salvage Retroperitoneal and Pelvic Lymph Node Dissection for 'Node-Only' Recurrent Prostate Cancer: Technique and Initial Series.
    J Urol. 2018;199:875-876.
    PubMed    


  451. SIEGEL C
    Re: Functional and Targeted Lymph Node Imaging in Prostate Cancer: Current Status and Future Challenges.
    J Urol. 2018;199:873.
    PubMed    


    March 2018
  452. WEI C, Li C, Szewczyk-Bieda M, Upreti D, et al
    Performance characteristics of transrectal shear wave elastography (SWE) imaging in the evaluation of clinically localised prostate cancer: a prospective study.
    J Urol. 2018 Mar 29. pii: S0022-5347(18)42856-X. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


  453. SHAH N, Ioffe V
    Re: Trends in Prostate Cancer Incidence Rates and Prevalence of Prostate Specific Antigen Screening by Socioeconomic Status and Regions in the United States, 2004 to 2013: K. A. Houston, J. King, J. Li and A. Jemal J Urol 2018;199:676-682.
    J Urol. 2018 Mar 26. pii: S0022-5347(18)42402.
    PubMed    


  454. PATEL N, Hu JC
    Re: Recent Changes in Prostate Cancer Screening Practices and Epidemiology: D. J. Lee, K. Mallin, A. J. Graves, S. S. Chang, D. F. Penson, M. J. Resnick and D. A. Barocas J Urol 2017;198:1230-1240.
    J Urol. 2018 Mar 16. pii: S0022-5347(18)30117-4. doi: 10.1016/j.juro.2018.
    PubMed    


  455. KLOTZ L, Loblaw A, Siemens R, Ouellette P, et al
    A phase II, randomized, multicentre study comparing 10 months versus 4 months of degarelix (Firmagon(R)) therapy in prolonging the off treatment interval in men with localized prostate cancer receiving intermittent androgen deprivation therapy for bio
    J Urol. 2018 Mar 10. pii: S0022-5347(18)42502-5. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


  456. RANDALL S, Boyd J, Fuller E, Brooks C, et al
    The effect of vasectomy reversal on prostate cancer risk: International meta-analysis of 684,660 men with vasectomies.
    J Urol. 2018 Mar 7. pii: S0022-5347(18)42489-5. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


  457. PATEL N, Halpern JA, Kasabwala K, Cricco-Lizza E, et al
    Multiple regions of interest on multi-parametric magnetic resonance imaging are not associated with increased detection of clinically significant prostate cancer on fusion biopsy.
    J Urol. 2018 Mar 5. pii: S0022-5347(18)42470-6. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


    February 2018
  458. VAN STAM MA, Pieterse AH, van der Poel HG, Bosch JLHR, et al
    Shared Decision-Making in Prostate Cancer Care: Encouraging every patient to be actively involved in decision-making, or ensuring patients' preferred level of involvement?
    J Urol. 2018 Feb 28. pii: S0022-5347(18)42403.
    PubMed     Abstract available


  459. SAMPURNO F, Zheng J, Di Stefano L, Millar JL, et al
    Quality indicators for global benchmarking of localised prostate cancer management.
    J Urol. 2018 Feb 22. pii: S0022-5347(18)39377-7. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


  460. MARZOUK S, Naglie G, Tomlinson G, Duff Canning S, et al
    Impact of Androgen Deprivation Therapy on Self-reported Cognitive Function in Men with Prostate Cancer.
    J Urol. 2018 Feb 22. pii: S0022-5347(18)39379-0. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


  461. MORTEZAVI A, Marzendorfer O, Donati OF, Rizzi G, et al
    Diagnostic accuracy of mpMRI and fusion-guided targeted biopsy evaluated by transperineal template saturation prostate biopsy for the detection and characterization of prostate cancer.
    J Urol. 2018 Feb 20. pii: S0022-5347(18)39373-X. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


  462. BAPAT B
    Re: Urinary DNA Methylation Biomarkers for Noninvasive Prediction of Aggressive Disease in Patients with Prostate Cancer on Active Surveillance: F. Zhao, E. Olkhov-Mitsel, T. van der Kwast, J. Sykes, D. Zdravic, V. Venkateswaran, A. R. Zlotta, A. Lobl
    J Urol. 2018 Feb 8. pii: S0022-5347(18)30001-6. doi: 10.1016/j.juro.2017.
    PubMed    


  463. OZGUR BC
    Re: The Effect of Metformin Use during Docetaxel Chemotherapy on Prostate Cancer Specific and Overall Survival of Diabetic Patients with Castration Resistant Prostate Cancer: M. J. Mayer, L. H. Klotz and V. Venkateswaran J Urol 2017;197:1068-1075.
    J Urol. 2018 Feb 8. pii: S0022-5347(17)78117-7. doi: 10.1016/j.juro.2017.
    PubMed    


  464. NABHANI JA, Kuang R, Liu H, Kwan L, et al
    Health Changes in Low-income Men Transitioning from a State-funded Prostate Cancer Program to Comprehensive Insurance.
    J Urol. 2018 Feb 6. pii: S0022-5347(18)30183-6. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


  465. ATALA A
    Re: mTORC1-Dependent AMD1 Regulation Sustains Polyamine Metabolism in Prostate Cancer.
    J Urol. 2018;199:344-346.
    PubMed    


  466. TANEJA SS
    Re: Follow-up of Prostatectomy versus Observation for Early Prostate Cancer.
    J Urol. 2018;199:342-343.
    PubMed    


  467. SEFTEL AD
    Re: The Accuracy of Patients' Perceptions of the Risks Associated with Localised Prostate Cancer Treatments.
    J Urol. 2018;199:329.
    PubMed    


  468. SIEGEL C
    Re: Pattern and Distribution of Distant Metastases in Anaplastic Prostate Carcinoma: A Single-Institute Experience with 101 Patients.
    J Urol. 2018;199:325.
    PubMed    


  469. SUN M, Cole AP, Hanna N, Mucci LA, et al
    Cognitive Impairment in Men with Prostate Cancer Treated with Androgen Deprivation Therapy: A Systematic Review and Meta-Analysis.
    J Urol. 2018 Feb 1. pii: S0022-5347(18)30109-5. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available


    January 2018
  470. LOPCI E, Saita A, Lazzeri M, Lughezzani G, et al
    (68)Ga-PSMA PET/CT for primary diagnosis of prostate cancer in men with contraindications to or negative mpMRI: a prospective observational study.
    J Urol. 2018 Jan 31. pii: S0022-5347(18)30172-1. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


  471. LUNDGREN PO, Kjellman A, Norming U, Gustafsson O, et al
    Long-term outcome of a single intervention Population based Prostate Cancer Screening Study.
    J Urol. 2018 Jan 31. pii: S0022-5347(18)30173-3. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


  472. PRENDEVILLE S, Gertner M, Maganti M, Pintilie M, et al
    Role of MRI-targeted Biopsy in Detection of Prostate Cancer Harbouring Adverse Pathological Features of Intraductal Carcinoma and Invasive Cribriform Carcinoma.
    J Urol. 2018 Jan 31. pii: S0022-5347(18)30175-7. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


  473. LEE JS, Lee HS, Ha JS, Han KS, et al
    Subcutaneous fat distribution is a prognostic biomarker for men with castration-resistant prostate cancer.
    J Urol. 2018 Jan 20. pii: S0022-5347(18)30106-X. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


  474. CHALFIN HJ, Glavaris SA, Malihi PD, Sperger JM, et al
    Prostate Cancer Disseminated Tumor Cells are Rarely Detected in the Bone Marrow of Localized Patients Undergoing Radical Prostatectomy Across Multiple Rare Cell Detection Platforms.
    J Urol. 2018 Jan 12. pii: S0022-5347(18)30065-X. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


  475. SANDA MG, Cadeddu JA, Kirkby E, Chen RC, et al
    Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. Part II: Recommended Approaches and Details of Specific Care Options.
    J Urol. 2018 Jan 10. pii: S0022-5347(18)30014-4. doi: 10.1016/j.juro.2018.
    PubMed     Abstract available


  476. NGUYEN DP, Vertosick EA, Sharma V, Corradi RB, et al
    Does subclassification of pathologically organ-confined (pT2) prostate cancer provide prognostic discrimination of outcomes after radical prostatectomy?
    J Urol. 2018 Jan 4. pii: S0022-5347(18)30005-3. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available


  477. KAPLAN SA
    Re: Long-Term Consequences of Finasteride vs Placebo in the Prostate Cancer Prevention Trial.
    J Urol. 2018;199:7-8.
    PubMed    


  478. TANEJA SS
    Re: Surrogate End Points for All-Cause Mortality in Men with Localized Unfavorable-Risk Prostate Cancer Treated with Radiation Therapy vs Radiation Therapy plus Androgen Deprivation Therapy: A Secondary Analysis of a Randomized Clinical Trial.
    J Urol. 2018;199:28.
    PubMed    


  479. TANEJA SS
    Re: Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer.
    J Urol. 2018;199:26-28.
    PubMed    


  480. PENSON DF
    Re: Testosterone Replacement Therapy and Risk of Favorable and Aggressive Prostate Cancer.
    J Urol. 2018;199:19-20.
    PubMed    


  481. CADEDDU JA
    Re: Near-Infrared Intraoperative Molecular Imaging Can Identify Metastatic Lymph Nodes in Prostate Cancer.
    J Urol. 2018;199:13-14.
    PubMed    


  482. SALAMI SS
    Editorial Comment.
    J Urol. 2018;199:104.
    PubMed    


  483. SONN G
    Editorial Comment.
    J Urol. 2018;199:104-105.
    PubMed    


  484. GHANI KR, Miller DC, Montie JE
    Editorial Comment.
    J Urol. 2018;199:96-97.
    PubMed    


  485. JOHNSON DC, Litwin MS
    Editorial Comment.
    J Urol. 2018;199:96.
    PubMed    


  486. PATEL NA, Kasabwala K, Hu JC
    Editorial Comment.
    J Urol. 2018;199:138-139.
    PubMed    


  487. NAHAR B, Parekh DJ
    Editorial Comment.
    J Urol. 2018;199:138.
    PubMed    


  488. BHINDI B
    Editorial Comment.
    J Urol. 2018;199:87-88.
    PubMed    


  489. KAPOOR DA
    A History of the United States Preventive Services Task Force: Its Expanding Authority and Need for Reform.
    J Urol. 2018;199:37-39.
    PubMed    


  490. TETREAULT-LAFLAMME A, Crook J, Hamm J, Pickles T, et al
    Long-Term Prostate Specific Antigen Stability and Predictive Factors of Failure after Permanent Seed Prostate Brachytherapy.
    J Urol. 2018;199:120-125.
    PubMed     Abstract available


  491. LUDWIG WW, Feng Z, Trock BJ, Humphreys E, et al
    Prostate Specific Antigen Testing after Radical Prostatectomy-Can We Stop at 20 Years?
    J Urol. 2018;199:114-119.
    PubMed     Abstract available


    December 2017
  492. OROM H, Biddle C, Underwood W 3rd, Nelson CJ, et al
    Worse urinary, sexual, and bowel function cause emotional distress and vice versa in men treated for prostate cancer.
    J Urol. 2017 Dec 26. pii: S0022-5347(17)78180-3. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available


  493. BERNSTEIN AN, Shoag JE, Golan R, Halpern JA, et al
    Contemporary Incidence & Outcomes of Prostate Cancer Lymph Node Metastases.
    J Urol. 2017 Dec 26. pii: S0022-5347(17)78181-5. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available


  494. AGHAZADEH MA, Frankel J, Belanger M, McLaughlin T, et al
    NCCN Favorable Intermediate Risk Prostate Cancer Patients: Is Active Surveillance Appropriate?
    J Urol. 2017 Dec 26. pii: S0022-5347(17)78182-7. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available


  495. LIU RSC, Olkhov-Mitsel E, Jeyapala R, Zhao F, et al
    Assessment of serum microRNA biomarkers for predicting reclassification of prostate cancer patients on active surveillance.
    J Urol. 2017 Dec 12. pii: S0022-5347(17)78068-8. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available


  496. VASAVADA SR, Dobbs RW, Kajdacsy-Balla AA, Abern MR, et al
    Inflammation on Prostate Needle Biopsy is Associated with Lower Prostate Cancer Risk: A Meta-Analysis.
    J Urol. 2017 Dec 12. pii: S0022-5347(17)78097-4. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available


  497. GEARMAN DJ, Morlacco A, Cheville JC, Rangel LJ, et al
    Comparison of Pathological and Oncologic Outcomes in "Favorable Risk" GS 3+4 and Low Risk GS6 Prostate Cancer: Considerations for Active Surveillance.
    J Urol. 2017 Dec 7. pii: S0022-5347(17)78036-6. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available


  498. ATALA A
    Re: Genomic Hallmarks of Localized, Non-Indolent Prostate Cancer.
    J Urol. 2017;198:1213.
    PubMed    


  499. ATALA A
    Re: The Metabolic Co-Regulator PGC1alpha Suppresses Prostate Cancer Metastasis.
    J Urol. 2017;198:1212-1214.
    PubMed    


  500. TANEJA SS
    Re: Associations of Luminal and Basal Subtyping of Prostate Cancer with Prognosis and Response to Androgen Deprivation Therapy.
    J Urol. 2017;198:1211.
    PubMed    


  501. TANEJA SS
    Re: Association between Combined TMPRSS2:ERG and PCA3 RNA Urinary Testing and Detection of Aggressive Prostate Cancer.
    J Urol. 2017;198:1210-1211.
    PubMed    


  502. TANEJA SS
    Re: Impact of Ga-68 PSMA-11 PET on Management in Patients with Biochemically Recurrent Prostate Cancer.
    J Urol. 2017;198:1209-1210.
    PubMed    


  503. TANEJA SS
    Re: Systematic Review Links the Prevalence of Intraductal Carcinoma of the Prostate to Prostate Cancer Risk Categories.
    J Urol. 2017;198:1208-1211.
    PubMed    


  504. MOREY AF
    Re: Radiation-Induced Complex Anterior Urinary Fistulation for Prostate Cancer: A Retrospective Multicenter Study from the Trauma and Urologic Reconstruction Network of Surgeons (TURNS).
    J Urol. 2017;198:1201-1203.
    PubMed    


  505. PENSON DF
    Re: Treatment Decision Regret among Long-Term Survivors of Localized Prostate Cancer: Results from the Prostate Cancer Outcomes Study.
    J Urol. 2017;198:1200.
    PubMed    


  506. SANDA MG, Cadeddu JA, Kirkby E, Chen RC, et al
    Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline, PART I.
    J Urol. 2017 Dec 1. pii: S0022-5347(17)78003-2. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available


    November 2017
  507. HASSAN O, Han M, Zhou A, Paulk A, et al
    Incidence of Extra-Prostatic Extension at Radical Prostatectomy with Pure Gleason Score 3+3=6 (Grade Group 1) Cancer: Implications for Whether Gleason Score 6 Prostate Cancer Should be Renamed as "not Cancer" and for Selection Criteria for Active Surv
    J Urol. 2017 Nov 15. pii: S0022-5347(17)77915-3. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available


  508. PISHGAR F, Ebrahimi H, Moghaddam SS, Fitzmaurice C, et al
    Global, Regional and National Burden of Prostate Cancer, 1990 - 2015: Results from the Global Burden of Disease Study 2015.
    J Urol. 2017 Nov 9. pii: S0022-5347(17)77883-4. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available


  509. TANEJA SS
    Re: Weight Change, Obesity and Risk of Prostate Cancer Progression among Men with Clinically Localized Prostate Cancer.
    J Urol. 2017;198:982.
    PubMed    


  510. TANEJA SS
    Re: Effective Combinatorial Immunotherapy for Castration-Resistant Prostate Cancer.
    J Urol. 2017;198:982-983.
    PubMed    


  511. TANEJA SS
    Re: Prognostic Utility of Biopsy-Derived Cell Cycle Progression Score in Patients with National Comprehensive Cancer Network Low-Risk Prostate Cancer Undergoing Radical Prostatectomy: Implications for Treatment Guidance.
    J Urol. 2017;198:981.
    PubMed    


  512. TANEJA SS
    Re: Treatment Decision Regret among Long-Term Survivors of Localized Prostate Cancer: Results from the Prostate Cancer Outcomes Study.
    J Urol. 2017;198:980-983.
    PubMed    


    October 2017
  513. HALPERN JA, Oromendia C, Shoag JE, Mittal S, et al
    Utility of Digital Rectal Examination (DRE) as an Adjunct to Prostate Specific Antigen (PSA) in the Detection of Clinically Significant Prostate Cancer.
    J Urol. 2017 Oct 20. pii: S0022-5347(17)77762-2. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available


  514. AUDENET F, Vertosick EA, Fine SW, Sjoberg DD, et al
    Biopsy Core Features are Poor Predictors of Adverse Pathology in Men with Grade Group 1 Prostate Cancer.
    J Urol. 2017 Oct 10. pii: S0022-5347(17)77714-2. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available


  515. ATALA A
    Re: Genome-Wide Association Study of Prostate-Specific Antigen Levels Identifies Novel Loci Independent of Prostate Cancer.
    J Urol. 2017;198:747.
    PubMed    


  516. TANEJA SS
    Re: Presence of Invasive Cribriform or Intraductal Growth at Biopsy Outperforms Percentage Grade 4 in Predicting Outcome of Gleason Score 3+4=7 Prostate Cancer.
    J Urol. 2017;198:745.
    PubMed    


  517. PENSON DF
    Re: Association between Radiation Therapy, Surgery, or Observation for Localized Prostate Cancer and Patient-Reported Outcomes after 3 Years.
    J Urol. 2017;198:744-745.
    PubMed    


  518. TANEJA SS
    Re: Association between Radiation Therapy, Surgery, or Observation for Localized Prostate Cancer and Patient-Reported Outcomes after 3 Years.
    J Urol. 2017;198:743-744.
    PubMed    


  519. TANEJA SS
    Re: Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death.
    J Urol. 2017;198:742-743.
    PubMed    


  520. TANEJA SS
    Re: Active Surveillance in Younger Men with Prostate Cancer.
    J Urol. 2017;198:741-745.
    PubMed    


  521. PENSON DF
    Re: Sharp Decline in Prostate Cancer Treatment among Men in the General Population, but Not among Diagnosed Men.
    J Urol. 2017;198:734-735.
    PubMed    


  522. GRIEBLING TL
    Re: Current Impact of Age and Comorbidity Assessment on Prostate Cancer Treatment Choice and Over/Undertreatment Risk.
    J Urol. 2017;198:724.
    PubMed    


  523. GRIEBLING TL
    Re: Comorbidity and Age Cannot Explain Variation in Life Expectancy Associated with Treatment of Non-Metastatic Prostate Cancer.
    J Urol. 2017;198:723.
    PubMed    


  524. GRIEBLING TL
    Re: Which Better Predicts Mortality among Older Men, a Prostate Cancer (PCa) Diagnosis or Vulnerability on the Vulnerable Elders Survey (VES-13)? A Retrospective Cohort Study.
    J Urol. 2017;198:723-724.
    PubMed    


    September 2017
  525. HOUSTON KA, King J, Li J, Jemal A, et al
    Trends in Prostate Cancer Incidence Rates and Prevalence of Prostate-Specific Antigen Screening by Socioeconomic Status and Regions in the US, 2004- 2013.
    J Urol. 2017 Sep 28. pii: S0022-5347(17)77650-1. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available


  526. HEILBRUN LK, Powell IJ
    Re: Pathological and Biochemical Outcomes among African-American and Caucasian Men with Low Risk Prostate Cancer in the SEARCH Database: Implications for Active Surveillance Candidacy: M. S. Leapman, S. J. Freedland, W. J. Aronson, C. J. Kane, M. K. T
    J Urol. 2017 Sep 26. pii: S0022-5347(17)77419-8. doi: 10.1016/j.juro.2017.
    PubMed    


  527. TOSOIAN JJ, Carter HB
    Patients with Intermediate Risk Prostate Cancer May be Good Candidates for Active Surveillance: Con.
    J Urol. 2017 Sep 22. pii: S0022-5347(17)77388-0. doi: 10.1016/j.juro.2017.
    PubMed    


  528. SANDA MG
    Patients with Intermediate Risk Prostate Cancer May be Good Candidates for Active Surveillance: Pro.
    J Urol. 2017 Sep 22. pii: S0022-5347(17)77389-2. doi: 10.1016/j.juro.2017.
    PubMed    


  529. XU X, Zhang X, Zhong Y, Saad F, et al
    Dynamic Patterns of Testosterone Levels within Individuals and Risk of Prostate Cancer among Hypogonadal Men: A Longitudinal Study.
    J Urol. 2017 Sep 20. pii: S0022-5347(17)77561-1. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available


  530. NGUYEN HG, Welty C, Lindquist K, Ngo V, et al
    Validation of GEMCaP as a DNA based biomarker to predict prostate cancer recurrence after radical prostatectomy.
    J Urol. 2017 Sep 20. pii: S0022-5347(17)77554-4. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available


  531. SHIOTA M, Fujimoto N, Takeuchi A, Kashiwagi E, et al
    The association of polymorphisms in the gene encoding gonadotropin releasing hormone with serum testosterone level during androgen-deprivation therapy and prognosis in metastatic prostate cancer.
    J Urol. 2017 Sep 20. pii: S0022-5347(17)77562-3. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available


  532. NYAME YA, Grimberg DC, Greene DJ, Gupta K, et al
    Genomic Scores are Independent of Disease Volume in Men with Favorable Risk Prostate Cancer: Implications for Choosing Men for Active Surveillance.
    J Urol. 2017 Sep 20. pii: S0022-5347(17)77563-5. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available


  533. GARCIA-REYES K, Nguyen HG, Zagoria RJ, Shinohara K, et al
    Impact of lesion visibility on transrectal ultrasound on the prediction of clinically significant prostate cancer (Gleason score >/= 3+4) with TRUS-MRI fusion biopsy.
    J Urol. 2017 Sep 20. pii: S0022-5347(17)77560-X. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available


  534. NEHRA A, Parker WP, Haloi R, Park SS, et al
    Identification of Recurrence Sites Following Post-Prostatectomy Treatment for Prostate Cancer Using 11C-Choline Positron Emission Tomography and Multiparametric Pelvic MRI.
    J Urol. 2017 Sep 12. pii: S0022-5347(17)77497-6. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available


  535. ORCZYK C, Emberton M
    Re: Magnetic Resonance Imaging Underestimation of Prostate Cancer Geometry: Use of Patient Specific Molds to Correlate Images with Whole Mount Pathology: A. Priester, S. Natarajan, P. Khoshnoodi, D. J. Margolis, S. S. Raman, R. E. Reiter, J. Huang, W.
    J Urol. 2017 Sep 6. pii: S0022-5347(17)77256-4. doi: 10.1016/j.juro.2017.
    PubMed    


  536. ATALA A
    Re: MicroRNA-141 Suppresses Prostate Cancer Stem Cells and Metastasis by Targeting a Cohort of Pro-Metastasis Genes.
    J Urol. 2017;198:486.
    PubMed    


  537. ATALA A
    Re: AKT-Mediated Stabilization of Histone Methyltransferase WHSC1 Promotes Prostate Cancer Metastasis.
    J Urol. 2017;198:485-487.
    PubMed    


  538. TANEJA SS
    Re: Videotaping of Surgical Procedures and Outcomes following Extraperitoneal Laparoscopic Radical Prostatectomy for Clinically Localized Prostate Cancer.
    J Urol. 2017;198:483-484.
    PubMed    


  539. SEFTEL AD
    Re: Association between Radiation Therapy, Surgery, or Observation for Localized Prostate Cancer and Patient-Reported Outcomes after 3 Years.
    J Urol. 2017;198:466-468.
    PubMed    


  540. TEETER AE, Griffin K, Howard LE, Aronson WJ, et al
    Does early PSADT (ePSADT) after Radical Prostatectomy, Calculated prior to PSA Recurrence, Correlate with Prostate Cancer Outcomes? -A Report from the SEARCH Database Group.
    J Urol. 2017 Sep 1. pii: S0022-5347(17)77427-7. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available


    August 2017
  541. TOMBAL B, Borre M, Rathenborg P, Werbrouck P, et al
    Long-term Anti-tumor Activity and Safety of Enzalutamide Monotherapy in Hormone-naive Prostate Cancer: 3-year, Open-label, Follow-up Results.
    J Urol. 2017 Aug 31. pii: S0022-5347(17)77422-8. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available


  542. CASTELLO A, Boldo E, Amiano P, Castano-Vinyals G, et al
    Mediterranean dietary pattern is associated to low risk of aggressive prostate cancer: MCC-Spain study.
    J Urol. 2017 Aug 22. pii: S0022-5347(17)77385-5. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available


  543. SIEMENS DR, Klotz L, Heidenreich A, Chowdhury S, et al
    Efficacy and Safety of Enzalutamide vs Bicalutamide in Younger and Older Patients with Metastatic Castration-resistant Prostate Cancer in the TERRAIN Trial.
    J Urol. 2017 Aug 18. pii: S0022-5347(17)77377-6. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available


  544. GARCIA-BARRERAS S, Sanchez-Salas R, Sivaraman A, Barret E, et al
    Partial gland ablation versus radical prostatectomy Comparative Analysis of Partial Gland Ablation and Radical Prostatectomy to Treat Low- and Intermediate-risk Prostate Cancer: Oncologic and Functional Outcomes.
    J Urol. 2017 Aug 17. pii: S0022-5347(17)77373-9. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available


  545. SHRESTHA E, White JR, Yu SH, Kulac I, et al
    Profiling the Urinary Microbiome in Men with Positive versus Negative Biopsies for Prostate Cancer.
    J Urol. 2017 Aug 7. pii: S0022-5347(17)77253-9. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available


  546. DAI C, Ganesan V, Zabell J, Nyame YA, et al
    Impact of 5alpha-reductase inhibitors on disease reclassification among men on active surveillance for localized prostate cancer with favorable features.
    J Urol. 2017 Aug 5. pii: S0022-5347(17)77259-X. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available


  547. AUFFENBERG GB, Lane BR, Linsell S, Brachulis A, et al
    A Roadmap for improving the management of men with favorable-risk prostate cancer.
    J Urol. 2017 Aug 3. pii: S0022-5347(17)77250-3. doi: 10.1016/j.juro.2017.
    PubMed    


  548. ATALA A
    Re: SOX2 Promotes Lineage Plasticity and Antiandrogen Resistance in TP53- and RB1-Deficient Prostate Cancer.
    J Urol. 2017;198:259.
    PubMed    


  549. TANEJA SS
    Re: Change in Salvage Radiotherapy Management Based on Guidance with FACBC (Fluciclovine) PET/CT in Postprostatectomy Recurrent Prostate Cancer.
    J Urol. 2017;198:256-257.
    PubMed    


  550. TANEJA SS
    Re: Padeliporfin Vascular-Targeted Photodynamic Therapy versus Active Surveillance in Men with Low-Risk Prostate Cancer (CLIN1001 PCM301): An Open-Label, Phase 3, Randomised Controlled Trial.
    J Urol. 2017;198:255-257.
    PubMed    


    July 2017
  551. SAMMON JD, Serrell EC, Karabon P, Leow JJ, et al
    Prostate Cancer Screening in Early Medicaid Expansion States.
    J Urol. 2017 Jul 29. pii: S0022-5347(17)77241-2. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available


  552. TAPLIN ME, Armstrong AJ, Lin P, Krivoshik A, et al
    Clinical Outcomes of Chemotherapy-Naive Men with Metastatic Castration-Resistant Prostate Cancer and Low Baseline PSA Treated with Enzalutamide vs Placebo.
    J Urol. 2017 Jul 20. pii: S0022-5347(17)77187-X. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available


  553. TAMMELA TL, Haggman M, Ladjevardi S, Taari K, et al
    An Intraprostatic Modified Release Formulation of Antiandrogen 2-Hydroxyflutamide for Localized Prostate Cancer.
    J Urol. 2017 Jul 20. pii: S0022-5347(17)77188-1. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available


  554. GORIN MA, Rowe SP, Patel HD, Vidal I, et al
    PSMA-targeted 18F-DCFPyL PET/CT in the Preoperative Staging of Men with High-risk Prostate Cancer: Results of a Prospective Phase II Single-Center Study.
    J Urol. 2017 Jul 20. pii: S0022-5347(17)77186-8. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available


  555. CHANG E, Jones TA, Natarajan S, Sharma D, et al
    Value of Tracking Biopsy in Men Undergoing Active Surveillance of Prostate Cancer.
    J Urol. 2017 Jul 17. pii: S0022-5347(17)77144-3. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available


  556. YANG L, Kibel AS, Colditz GA, Pakpahan R, et al
    Caution with Use of the Expanded Prostate Cancer Index Composite-50 Urinary Bother Scale: How Voiding Dysfunction Modifies Its Performance.
    J Urol. 2017 Jul 17. pii: S0022-5347(17)77147-9. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available


  557. STROUP SP, Moreira DM, Chen Z, Howard L, et al
    Biopsy-Detected Gleason Pattern 5 is Associated with Recurrence, Metastasis, and Mortality in a Cohort of Men with High-Risk Prostate Cancer.
    J Urol. 2017 Jul 11. pii: S0022-5347(17)77098-X. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available


  558. PENSON DF
    Re: Increase in Prostate Cancer Distant Metastases at Diagnosis in the United States.
    J Urol. 2017;198:104-105.
    PubMed    


  559. PENSON DF
    Re: Vasectomy and Prostate Cancer Incidence and Mortality in a Large US Cohort.
    J Urol. 2017;198:104-106.
    PubMed    


  560. ATALA A
    Re: Targeted Molecular-Genetic Imaging and Ligand-Directed Therapy in Aggressive Variant Prostate Cancer.
    J Urol. 2017;198:103-104.
    PubMed    


  561. ATALA A
    Re: Low CD38 Identifies Progenitor-Like Inflammation-Associated Luminal Cells that Can Initiate Human Prostate Cancer and Predict Poor Outcome.
    J Urol. 2017;198:103.
    PubMed    


  562. ATALA A
    Re: Rb1 and Trp53 Cooperate to Suppress Prostate Cancer Lineage Plasticity, Metastasis, and Antiandrogen Resistance.
    J Urol. 2017;198:102-104.
    PubMed    


  563. TANEJA SS
    Re: Diagnostic Accuracy of Multi-Parametric MRI and TRUS Biopsy in Prostate Cancer (PROMIS): A Paired Validating Confirmatory Study.
    J Urol. 2017;198:101-102.
    PubMed    


  564. TANEJA SS
    Re: Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer.
    J Urol. 2017;198:100-102.
    PubMed    


    June 2017
  565. BHINDI B, Karnes RJ, Rangel LJ, Mason RJ, et al
    Independent Validation of the American Joint Committee on Cancer 8th Edition Prostate Cancer Staging Classification.
    J Urol. 2017 Jun 29. pii: S0022-5347(17)77027-9. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available


  566. JONES TA, Chin J, Mcleod D, Barkin J, et al
    High-Intensity Focused Ultrasound for Radio-recurrent Prostate Cancer: A North American Clinical Trial.
    J Urol. 2017 Jun 23. pii: S0022-5347(17)76734-1. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available


  567. PALAPATTU GS
    Genomic Tests Should be Used to Help Guide Treatment of Prostate Cancer: Yes.
    J Urol. 2017 Jun 16. pii: S0022-5347(17)67196-9. doi: 10.1016/j.juro.2017.
    PubMed    


  568. PUNNEN S, Parekh DJ
    Genomic Tests Should be Used to Help Guide Treatment of Prostate Cancer: No.
    J Urol. 2017 Jun 16. pii: S0022-5347(17)67197-0. doi: 10.1016/j.juro.2017.
    PubMed    


  569. KIBEL AS
    Intermediate Risk Prostate Cancer and Active Surveillance: Maximize Utilization while Minimizing Failure.
    J Urol. 2017 Jun 16. pii: S0022-5347(17)74842-2. doi: 10.1016/j.juro.2017.
    PubMed    


  570. SEFTEL AD
    Re: Rasch Analysis of the Premature Ejaculation Diagnostic Tool (PEDT) and the International Index of Erectile Function (IIEF) in an Iranian Sample of Prostate Cancer Patients.
    J Urol. 2017;197:1534-1535.
    PubMed    


  571. KAPLAN SA
    Re: Interactions between Benign Prostatic Hyperplasia (BPH) and Prostate Cancer in Large Prostates: A Retrospective Data Review.
    J Urol. 2017;197:1531-1532.
    PubMed    


  572. ATALA A
    Re: Androgen Receptor Antagonists Compromise T Cell Response against Prostate Cancer Leading to Early Tumor Relapse.
    J Urol. 2017;197:1459.
    PubMed    


  573. ATALA A
    Re: Activation of Notch1 Synergizes with Multiple Pathways in Promoting Castration-Resistant Prostate Cancer.
    J Urol. 2017;197:1458-1459.
    PubMed    


  574. CADEDDU JA
    Re: Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Tissue in Patients with Localized Prostate Cancer: A Prospective Phase 1 Clinical Trial.
    J Urol. 2017;197:1457-1458.
    PubMed    


  575. TANEJA SS
    Re: Urologist-Level Correlation in the Use of Observation for Low- and High-Risk Prostate Cancer.
    J Urol. 2017;197:1456.
    PubMed    


  576. TANEJA SS
    Re: Mortality among Men with Advanced Prostate Cancer Excluded from the ProtecT Trial.
    J Urol. 2017;197:1456-1457.
    PubMed    


  577. DENIZE J, Nouhaud FX, Cornu JN, Pfister C, et al
    Re: Timing of Adverse Prostate Cancer Reclassification on First Surveillance Biopsy: Results from the Canary Prostate Cancer Active Surveillance Study: L. C. Macleod, W. J. Ellis, L. F. Newcomb, Y. Zheng, J. D. Brooks, P. R. Carroll, M. E. Gleave, R.
    J Urol. 2017 Jun 1. pii: S0022-5347(17)59378-7. doi: 10.1016/j.juro.2017.
    PubMed    


    May 2017
  578. YAN W, Shang Z, Zhou Z
    Re: Magnetic Resonance Imaging Underestimation of Prostate Cancer Geometry: Use of Patient Specific Molds to Correlate Images with Whole Mount Pathology: A. Priester, S. Natarajan, P. Khoshnoodi, D. J. Margolis, S. S. Raman, R. E. Reiter, J. Huang, W.
    J Urol. 2017 May 31. pii: S0022-5347(17)57834-9. doi: 10.1016/j.juro.2017.
    PubMed    


  579. TELOKEN PE, Li J, Woods CG, Cohen RJ, et al
    The impact of prostate cancer zonal origin on pathological parameters at radical prostatectomy and subsequent biochemical failure.
    J Urol. 2017 May 26. pii: S0022-5347(17)74541-7. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available


  580. TOMBAL B, Cornel EB, Persad R, Stari A, et al
    Clinical Outcomes and Testosterone Levels Following Continuous Androgen Deprivation in Patients with Relapsing or Locally Advanced Prostate Cancer: A Post Hoc Analysis of the ICELAND Study.
    J Urol. 2017 May 25. pii: S0022-5347(17)74503-X. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available


  581. FELDMAN AS, Meyer CP, Sanchez A, Krasnova A, et al
    Morbidity and Mortality of Locally Advanced Prostate Cancer: A Population-Based Analysis Comparing Radical Prostatectomy Versus External Beam Radiation.
    J Urol. 2017 May 25. pii: S0022-5347(17)74504-1. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available


  582. LEE DJ, Mallin K, Graves AJ, Chang SS, et al
    Recent changes in prostate cancer screening practices and prostate cancer epidemiology.
    J Urol. 2017 May 25. pii: S0022-5347(17)74517-X. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available


  583. HENRY MA, Howard DH, Davies BJ, Filson CP, et al
    Variation in Use of Prostate Biopsy Following Changes in Prostate Cancer Screening Guidelines.
    J Urol. 2017 May 6. pii: S0022-5347(17)64683-4. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available


  584. SEFTEL AD
    Re: Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer.
    J Urol. 2017;197:1266.
    PubMed    


  585. TANEJA SS
    Re: Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer.
    J Urol. 2017;197:1265-1266.
    PubMed    


  586. TANEJA SS
    Re: Development and Validation of a 24-Gene Predictor of Response to Postoperative Radiotherapy in Prostate Cancer: A Matched, Retrospective Analysis.
    J Urol. 2017;197:1264-1266.
    PubMed    


    April 2017
  587. GOLAN R, Bernstein AN, McClure TD, Sedrakyan A, et al
    Partial gland treatment of prostate cancer utilizing high-intensity focused ultrasound in the primary and salvage setting: a systematic review.
    J Urol. 2017 Apr 19. pii: S0022-5347(17)54786-2. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available


  588. NATARAJAN S, Jones TA, Priester AM, Geoghegan R, et al
    Focal Laser Ablation of Prostate Cancer: Feasibility of MRI/US Fusion for Guidance.
    J Urol. 2017 Apr 7. pii: S0022-5347(17)45433-4. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available


    March 2017
  589. DISTLER FA, Radtke JP, Bonekamp D, Kesch C, et al
    The value of PSA density in combination with PI-RADS for the accuracy of prostate cancer prediction.
    J Urol. 2017 Mar 31. pii: S0022-5347(17)43846-8. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available


  590. MEHRALIVAND S, Bednarova S, Shih JH, Mertan FV, et al
    Prospective Evaluation of Prostate Imaging-Reporting and Data System Version 2 Using the International Society of Urological Pathology Prostate Cancer Grade Group System.
    J Urol. 2017 Mar 31. pii: S0022-5347(17)43847-X. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available


  591. NYAME YA, Almassi N, Haywood SC, Greene DJ, et al
    Intermediate-Term Outcomes of Men with Very Low/Low and Intermediate/High Risk Prostate Cancer Managed by Active Surveillance.
    J Urol. 2017 Mar 24. pii: S0022-5347(17)42185-9. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available


  592. LEBDAI S, Bigot P, Leroux PA, Berthelot LP, et al
    Vascular-Targeted Photodynamic Therapy with Padeliporfin for Low Risk Prostate Cancer Treatment: Mid-Term Oncological Outcomes.
    J Urol. 2017 Mar 18. pii: S0022-5347(17)40346-6. doi: 10.1016/j.juro.2017.
    PubMed     Abstract available


    February 2017
  593. TANEJA SS
    Re: Study of Testosterone-Guided Androgen Deprivation Therapy in Management of Prostate Cancer.
    J Urol. 2017;197:398-399.
    PubMed    


    December 2016
  594. KAPLAN SA
    Re: Testosterone Replacement Therapy on the Natural History of Prostate Disease.
    J Urol. 2016;196:1713-1714.
    PubMed    


  595. SEFTEL AD
    Re: Variation in Testosterone Levels and Health-Related Quality of Life in Men Diagnosed with Prostate Cancer on Active Surveillance.
    J Urol. 2016;196:1723-1724.
    PubMed    


    June 2016
  596. KAPLAN SA
    Re: Resveratrol Reduces the Levels of Circulating Androgen Precursors but has No Effect on Testosterone, Dihydrotestosterone, PSA Levels or Prostate Volume. A 4-Month Randomised Trial in Middle-Aged Men.
    J Urol. 2016;195:1838.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: